<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7943011</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0248103</article-id><article-id pub-id-type="publisher-id">PONE-D-20-26246</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Diabetic Endocrinology</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Hormones</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Molecular Biology Assays and Analysis Techniques</subject><subj-group><subject>Gene Expression and Vector Techniques</subject><subj-group><subject>Protein Expression</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Molecular Biology Assays and Analysis Techniques</subject><subj-group><subject>Gene Expression and Vector Techniques</subject><subj-group><subject>Protein Expression</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Structures and Organelles</subject><subj-group><subject>Cell Membranes</subject><subj-group><subject>Membrane Proteins</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Hyperinsulinemia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Signal transduction</subject><subj-group><subject>Cell signaling</subject><subj-group><subject>Signaling cascades</subject><subj-group><subject>MAPK signaling cascades</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Metastasis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Basic Cancer Research</subject><subj-group><subject>Metastasis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Malignant Tumors</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line</article-title><alt-title alt-title-type="running-head">Changes in protein expression due to metformin treatment and hyperinsulinemia</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4915-0870</contrib-id><name><surname>Lange</surname><given-names>Carsten</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Project administration</role><role content-type="https://casrai.org/credit/">Visualization</role><role content-type="https://casrai.org/credit/">Writing &#x02013; original draft</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Machado Weber</surname><given-names>Amanda</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Project administration</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>Ronny</given-names></name><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6177-1042</contrib-id><name><surname>Schroeder</surname><given-names>Christoph</given-names></name><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Methodology</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Strowitzki</surname><given-names>Thomas</given-names></name><role content-type="https://casrai.org/credit/">Funding acquisition</role><role content-type="https://casrai.org/credit/">Resources</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Germeyer</surname><given-names>Ariane</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Funding acquisition</role><role content-type="https://casrai.org/credit/">Project administration</role><role content-type="https://casrai.org/credit/">Resources</role><role content-type="https://casrai.org/credit/">Supervision</role><role content-type="https://casrai.org/credit/">Writing &#x02013; original draft</role><role content-type="https://casrai.org/credit/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Gynecologic Endocrinology and Fertility Disorders, Women&#x02019;s Hospital, Ruprecht-Karls University of Heidelberg, Heidelberg, Germany</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Sciomics GmbH, Heidelberg, Germany</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Jeong</surname><given-names>Jae-Wook</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Michigan State University, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have read the journal&#x02019;s policy and have the following competing interests to declare: R.S. is a paid employee of Sciomics GmbH, C.S. is founder and shareholder of Sciomics GmbH. There are no patents, products in development or marketed products to declare based on the data presented. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><corresp id="cor001">* E-mail: <email>carsten.lange@med.uni-heidelberg.de</email></corresp></author-notes><pub-date pub-type="epub"><day>9</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>16</volume><issue>3</issue><elocation-id>e0248103</elocation-id><history><date date-type="received"><day>21</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>21</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 Lange et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Lange et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0248103.pdf"/><abstract><p>The incidence of endometrial cancer (EC) has increased over the past years and mainly affects women above the age of 45 years. Metabolic diseases such as obesity and type II diabetes mellitus as well as associated conditions like polycystic ovary syndrome (PCOS), insulin resistance and hyperinsulinemia lead to elevated levels of circulating estrogens. Increased estrogen concentrations, in turn, further trigger the proliferation of endometrial cells and thus promote EC development and progression, especially in the absence of progesterone as seen in postmenopausal women. Elevated blood glucose levels in diabetic patients further contribute to the risk of EC development. Metformin is an insulin-sensitizing biguanide drug, commonly used in the treatment of type II diabetes mellitus, especially in obese patients. Besides its effects on glucose metabolism, metformin displayed anti-cancer effects in various cancer types, including EC. Direct anti-cancer effects of metformin target signaling pathways that are involved in cellular growth and proliferation, e.g. the AKT/PKB/mTOR pathway. Further proteins and pathways have been suggested as potential targets, but the underlying mechanism of action of metformin&#x02019;s anti-cancer activity is still not completely understood. In the present study, the effects of metformin on protein expression were investigated in the human EC cell line HEC-1A using an affinity proteomic approach. Cells were treated with 0.5 mmol/L metformin over a period of 7 days and changes in the expression pattern of 1,300 different proteins were compared to the expression in untreated control cells as well as insulin-treated cells. Insulin treatment (100 ng/mL) was incorporated into the study in order to implement a model for insulin resistance and associated hyperinsulinemia, conditions that are often observed in obese and diabetic patients. Furthermore, the culture medium was supplemented with 10 nmol/L &#x000df;-estradiol (E2) during treatments to mimic increased estrogen levels, a common risk factor for EC development. Based on the most prominent and significant changes in expression, a set of 80 proteins was selected and subjected to a more detailed analysis. The data revealed that metformin and insulin targeted similar pathways in the present study and mostly acted on proteins related to proliferation, migration and tumor immune response. These pathways may be affected in a tumor-promoting as well as a tumor-suppressing way by either metformin treatment or insulin supplementation. The consequences for the cells resulting from the detected expression changes were discussed in detail for several proteins. The presented data helps identify potential targets affected by metformin treatment in EC and allows for a better understanding of the mechanism of action of the biguanide drug&#x02019;s anti-cancer activity. However, further investigations are necessary to confirm the observations and conclusions drawn from the presented data after metformin administration, especially for proteins that were regulated in a favorable way, i.e. AKT3, CCND2, CD63, CD81, GFAP, IL5, IL17A, IRF4, PI3, and VTCN1. Further proteins might be of interest, where metformin counteracted unfavorable effects that have been induced by hyperinsulinemia.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>GE 1173/3-1</award-id><principal-award-recipient><name><surname>Germeyer</surname><given-names>Ariane</given-names></name></principal-award-recipient></award-group><funding-statement>"This study was financially supported by the Department of Gynecologic Endocrinology and Fertility Disorders (Women&#x02019;s Hospital, Ruprecht-Karls University of Heidelberg, Germany) and the German Research Foundation, DFG (grant: GE 1173/3-1 to A.G.). Sciomics GmbH provided funding for this study in the form of salaries for authors R.S. &#x00026; C.S., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the &#x02018;author contributions&#x02019; section." <ext-link ext-link-type="uri" xlink:href="https://www.klinikum.uni-heidelberg.de/frauenklinik-zentrum/gynaekologische-endokrinologie-und-fertilitaetsstoerungen">https://www.klinikum.uni-heidelberg.de/frauenklinik-zentrum/gynaekologische-endokrinologie-und-fertilitaetsstoerungen</ext-link><ext-link ext-link-type="uri" xlink:href="https://gepris.dfg.de/gepris/projekt/394654860?language=en">https://gepris.dfg.de/gepris/projekt/394654860?language=en</ext-link>.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="7"/><page-count count="22"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its <xref ref-type="sec" rid="sec010">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its <xref ref-type="sec" rid="sec010">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>1. Introduction</title><p>Endometrial cancer (EC) is the 6<sup>th</sup> most common cancer in women and constitutes the leading malignancy of the female reproductive system in developed countries [<xref rid="pone.0248103.ref001" ref-type="bibr">1</xref>]. EC can be subdivided into an estrogen-dependent type I, and a less common (15&#x02013;25%) but more aggressive and invasive, estrogen-independent type II [<xref rid="pone.0248103.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pone.0248103.ref004" ref-type="bibr">4</xref>]. The incidence of EC has increased over the past years and mainly affects postmenopausal women while it is uncommon to be diagnosed under the age of 45 years [<xref rid="pone.0248103.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0248103.ref006" ref-type="bibr">6</xref>]. The high incidence and mortality in developed countries could be related to a higher prevalence of common risk factors such as obesity and type II diabetes mellitus [<xref rid="pone.0248103.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0248103.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0248103.ref008" ref-type="bibr">8</xref>]. Obesity and obesity-associated diseases such as polycystic ovary syndrome (PCOS) lead to elevated levels of circulating estrogens that, in turn, increase proliferation of endometrial cells and promote EC development, especially in the absence of progesterone [<xref rid="pone.0248103.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0248103.ref011" ref-type="bibr">11</xref>]. Elevated blood glucose levels of diabetic patients may further contribute to the risk of EC development via an increased glycolytic-lipogenic metabolism and the insulin-like growth factor (IGF) signaling pathway [<xref rid="pone.0248103.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0248103.ref013" ref-type="bibr">13</xref>].</p><p>Metformin is an insulin-sensitizing biguanide drug, commonly used in the treatment of type II diabetes mellitus [<xref rid="pone.0248103.ref014" ref-type="bibr">14</xref>], especially in obese patients [<xref rid="pone.0248103.ref015" ref-type="bibr">15</xref>]. Besides its effects on glucose metabolism, metformin displayed anti-cancer effects in various human cancer cell lines and diabetic patients with various cancer types [<xref rid="pone.0248103.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0248103.ref018" ref-type="bibr">18</xref>], including EC [<xref rid="pone.0248103.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0248103.ref021" ref-type="bibr">21</xref>]. The effects of metformin on malignant tissue may be direct or indirect. Indirect effects include a reduction in circulating glucose and insulin levels via a blockage of gluconeogenesis in the liver, which diminishes insulin resistance due to an inhibition of the IGF1 signaling pathway in tumor cells [<xref rid="pone.0248103.ref022" ref-type="bibr">22</xref>&#x02013;<xref rid="pone.0248103.ref024" ref-type="bibr">24</xref>]. Direct anti-cancer effects of metformin target signaling pathways that are involved in cellular growth and proliferation, e.g. by activation of adenosine monophosphate-activated protein kinase (AMPK), a key regulator in energy homeostasis. Upon activation by liver kinase B1 (LKB1), AMPK induces various tumor suppressor genes, e.g. phosphatase and tensin homolog (PTEN), and thus downregulates growth-related pathways, especially mammalian target of rapamycin (mTOR) signaling [<xref rid="pone.0248103.ref025" ref-type="bibr">25</xref>]. Alterations in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT/PKB)/mTOR pathway mediate EC growth and development and can be caused by a loss of PTEN or mutations of PI3K family members [<xref rid="pone.0248103.ref026" ref-type="bibr">26</xref>&#x02013;<xref rid="pone.0248103.ref030" ref-type="bibr">30</xref>]. Additionally, metformin may act on growth and proliferation independent of AMPK, e.g. via downregulation of the proliferation marker Kiel-67 antigen (MKI67), via the transcription factor paired box gene 2 (PAX2), or via Ras-related guanosine triphosphate hydrolases (Rag GTPases) [<xref rid="pone.0248103.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0248103.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pone.0248103.ref033" ref-type="bibr">33</xref>]. Growing attention was also given to the inhibition of mitochondrial respiratory-chain complex 1 (NADH:ubiquinone oxidoreductase) by metformin in recent years. Like AMPK, the complex is involved in cellular energy homeostasis, but a direct involvement of AMPK in this mechanism is still a matter of debate [<xref rid="pone.0248103.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0248103.ref034" ref-type="bibr">34</xref>&#x02013;<xref rid="pone.0248103.ref036" ref-type="bibr">36</xref>]. Further affected proteins and pathways like the inhibition of signal transducer and activator of transcription 3 (STAT3) [<xref rid="pone.0248103.ref037" ref-type="bibr">37</xref>], various routes of apoptosis induction [<xref rid="pone.0248103.ref038" ref-type="bibr">38</xref>], or regulation of microRNA (miRNA) [<xref rid="pone.0248103.ref039" ref-type="bibr">39</xref>] have been suggested as potential targets for the biguanide drug, but the underlying mechanism of action of metformin&#x02019;s anti-cancer activity is still not completely understood.</p><p>In the present study, the effects of metformin on the human EC cell line HEC-1A were investigated using an affinity proteomic approach. HEC-1A cells were derived from a moderately differentiated grade 2 endometrial adenocarcinoma of a 71-year-old woman and are characterized by a poor expression of estrogen receptor &#x003b1; (ER&#x003b1;) [<xref rid="pone.0248103.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0248103.ref041" ref-type="bibr">41</xref>]. However, HEC-1A cells express ER&#x003b2; and G protein-coupled estrogen receptor 1 (GPER) and therefore maintain a low estrogen sensitivity. Therefore, HEC-1A cells represent a postmenopausal model with low sensitivity for &#x000df;-estradiol (E2), which are able to form E2 from estrone (E1) to some extent [<xref rid="pone.0248103.ref042" ref-type="bibr">42</xref>]. Cells were treated long-term with metformin over a period of 7 days and changes in the expression pattern of 1,300 different proteins were compared to the expression in untreated control cells as well as insulin-treated cells. Insulin treatment was incorporated into the study in order to implement a model for insulin resistance and related hyperinsulinemia, conditions that are often observed in obese and prediabetic patients [<xref rid="pone.0248103.ref043" ref-type="bibr">43</xref>]. Although the HEC-1A cell line is characterized by low estrogen sensitivity, cells were additionally provided with E2 in order to mimic increased estrogen levels in the present study. Elevated estrogen levels represent a common risk factor for EC development and progression and are therefore essential for a realistic <italic>in vitro</italic> simulation of the environment in EC patients and women with increased risk for EC development [<xref rid="pone.0248103.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0248103.ref011" ref-type="bibr">11</xref>]. It was shown that E2 stimulates cellular proliferation, migration and growth of HEC-1A cells independent of ER&#x003b1; via a GPER-mediated activation of diacylglycerol kinase &#x003b1; (DGK&#x003b1;) [<xref rid="pone.0248103.ref044" ref-type="bibr">44</xref>]. With the presented data, we contribute to a better understanding of the anti-cancer activity of metformin as well as its underlying mechanism of action in EC cells.</p></sec><sec sec-type="materials|methods" id="sec002"><title>2. Methods</title><sec id="sec003"><title>2.1. Cell culture and metformin treatment</title><p>The human EC cell line HEC-1A (moderately differentiated grade 2 adenocarcinoma; HTB112, ATCC, Manassas, VA, USA) [<xref rid="pone.0248103.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0248103.ref041" ref-type="bibr">41</xref>] was cultured in Eagle&#x02019;s minimal essential medium (MEM, 5.5 mmol/L glucose, equivalent to 100 mg/dL; Sigma-Aldrich, Munich, Germany) supplemented with 10% (v/v) charcoal-stripped fetal bovine serum (FBS; Gibco, Waltham, MA, USA), 1% (v/v) non-essential amino acids (Sigma-Aldrich), 100 &#x003bc;g/mL streptomycin and 100 U/mL penicillin G (Gibco) at 37&#x000b0;C and 5% CO<sub>2</sub> in a humidified atmosphere. Cells were subcultured by detachment with 0.25% (v/v) trypsin/ethylenediaminetetraacetic acid (EDTA; Gibco) once a week and the medium was changed every 2&#x02013;3 days. Experiments were carried out in 25 cm<sup>2</sup> cell culture flasks (Greiner, Kremsm&#x000fc;nster, Austria) with a seeding density of 1.0 &#x000d7; 10<sup>5</sup> cells in 5 mL medium in duplicates. After seeding, cells were allowed to attach and grow for 24 h before treatment.</p><p>Cells were treated with either 0.5 mmol/L metformin or 100 ng/mL insulin in culture medium supplemented with 10 nmol/L &#x000df;-estradiol (E2; all reagents purchased from Sigma-Aldrich) for 7 days with medium changes and renewed treatments every 2 days. Control cells were treated with substance-free medium supplemented with 10 nmol/L E2.</p></sec><sec id="sec004"><title>2.2. Cell lysis and protein extraction</title><p>Cells were detached from the substrate surface by incubation with trypsin after a treatment period of 7 days. The medium was removed and substituted by fresh substance-containing medium 2 h prior harvesting. Aliquots of 5.0 &#x000d7; 10<sup>6</sup> cells were transferred to 1.5 mL tubes, washed with ice-cold phosphate-buffered saline (PBS; Sigma-Aldrich) and pellets were collected from three independent experiments and stored at -80&#x000b0;C until further analysis.</p></sec><sec id="sec005"><title>2.3. Proteomic analysis</title><p>Proteins were extracted with scioExtract buffer (Sciomics, Heidelberg, Germany) and total protein concentrations were measured with the bicinchoninic acid assay (BCA; Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer&#x02019;s protocol. The samples were labelled at an adjusted protein concentration with scioDye 1 and scioDye 2 (Sciomics) for 2 h. The reaction was stopped by an exchange of the buffer to PBS and proteins were analyzed in a dual-color approach using a reference-based design on nine scioDiscover antibody microarrays (Sciomics) targeting 1,300 different proteins with 1,830 antibodies in quadruplicates. Arrays were blocked with scioBlock (Sciomics) on a Hybstation 4800 (Tecan, Maennedorf, Switzerland) and afterwards incubated competitively using a dual-color approach. After incubation for 3 h, slides were washed with PBSTT, rinsed with 0.1% (v/v) PBS as well as water and subsequently dried with N<sub>2</sub>.</p></sec><sec id="sec006"><title>2.4. Data acquisition and bioinformatic analysis</title><p>Slide scanning was conducted using a PowerScanner (Tecan) with identical instrument laser power and adjusted photomultiplier tube (PMT) settings. Spot segmentation was performed with the GenePix Pro 6 software (Molecular Devices, San Jos&#x000e9;, CA, USA). Acquired raw data were analyzed using the linear models for microarray data (LIMMA) package [<xref rid="pone.0248103.ref045" ref-type="bibr">45</xref>] of R-Bioconductor [<xref rid="pone.0248103.ref046" ref-type="bibr">46</xref>] after uploading the median signal intensities. For normalization, a specialized invariant Lowess method was applied [<xref rid="pone.0248103.ref047" ref-type="bibr">47</xref>]. For the sample analysis, a one-factorial linear model was fitted with LIMMA resulting in a two-sided t-test or F-test, based on moderated statistics. All presented <italic>p</italic> values were adjusted for multiple testing by controlling the false discovery rate according to Benjamini and Hochberg [<xref rid="pone.0248103.ref048" ref-type="bibr">48</xref>]. Differences in protein abundance between samples were presented as log<sub>2</sub>-fold changes (log<sub>2</sub>FC). Proteins were defined as differentially expressed, if |log<sub>2</sub>FC| were &#x02265; 0.5 or the adjusted <italic>p</italic> values were &#x02264; 0.05. Proteins were defined as significantly differential for |log<sub>2</sub>FC| &#x02265; 0.5 and a simultaneous adjusted <italic>p</italic> value &#x02264; 0.05. All differential proteins that met one or both criteria were graphically displayed in an area-proportional Venn diagram using the BioVenn application [<xref rid="pone.0248103.ref049" ref-type="bibr">49</xref>] and were subjected to STRING (search tool for the retrieval of interacting genes/proteins) analysis for the visualization of protein networks [<xref rid="pone.0248103.ref050" ref-type="bibr">50</xref>]. Protein clusters were identified for biological processes and molecular functions based on the gene ontology (GO) database [<xref rid="pone.0248103.ref051" ref-type="bibr">51</xref>, <xref rid="pone.0248103.ref052" ref-type="bibr">52</xref>]. The database for annotation, visualization, and integrated discovery (DAVID) [<xref rid="pone.0248103.ref053" ref-type="bibr">53</xref>&#x02013;<xref rid="pone.0248103.ref055" ref-type="bibr">55</xref>] was used for a more targeted pathway analysis (GO and Kyoto encyclopedia of genes and genomes (KEGG) pathway database [<xref rid="pone.0248103.ref056" ref-type="bibr">56</xref>]) that distinguished between proteins regulated by either metformin or insulin treatment. Pathways with protein counts &#x02265; 10% of the total number of analyzed proteins that simultaneously displayed <italic>p</italic> values &#x02264; 0.001 (from DAVID analysis) were presented.</p></sec></sec><sec sec-type="results" id="sec007"><title>3. Results</title><p>Hierarchical clustering of the samples was performed with the differential data set and a separation between the groups was observed except for one control sample (Control_3), which clustered with the insulin group (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1D</xref>). Furthermore, one metformin sample (Metformin_3) was identified as an outlier and removed from the proteomic analysis.</p><fig id="pone.0248103.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.g001</object-id><label>Fig 1</label><caption><title>Proteomic analysis of endometrial cancer cells after treatment with metformin or insulin.</title><p>Protein lysates of HEC-1A cells were collected 7 days after repeated administration of 0.5 mmol/L metformin or 100 ng/mL insulin and subjected to scioDiscover antibody microarrays targeting 1,300 different proteins. Untreated cells served as the reference control sample. Proteins were defined as significantly differential for |log<sub>2</sub>FC| &#x02265; 0.5 and an adjusted <italic>p</italic> value &#x02264; 0.05; n = 3. (<bold>A</bold>&#x02013;<bold>C</bold>) Volcano plots for each treatment group display the distribution of proteins that were differently expressed after metformin (<bold>A</bold>) or insulin (<bold>B</bold>) administration compared to control samples or between metformin and insulin treatments (<bold>C</bold>). (<bold>D</bold>) Hierarchical clustering of samples based on differential protein data. One sample (Metformin_3) was identified as an outlier and removed from proteomic analysis. (<bold>E</bold>) Venn diagram of differentially expressed proteins after treatment with metformin or insulin (metformin/insulin vs. control) or between both treatment groups (metformin vs. insulin).</p></caption><graphic xlink:href="pone.0248103.g001"/></fig><p>Compared to untreated control cells, metformin-treated cells differentially expressed 47 proteins (with |log<sub>2</sub>FC| &#x02265; 0.5 and/or adjusted <italic>p</italic> value &#x02264; 0.05), of which 15 proteins were exclusively changed by the biguanide drug and not during hyperinsulinemia (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1E</xref> and <xref rid="pone.0248103.t001" ref-type="table">Table 1</xref>). A total of 15 out of 47 proteins met both of the above-mentioned criteria (log<sub>2</sub>FC| &#x02265; 0.5 and adjusted <italic>p</italic> value &#x02264; 0.05) and thus were significantly differential expressed in comparison to untreated control samples (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1A</xref>, <xref rid="pone.0248103.t001" ref-type="table">Table 1</xref> and <xref ref-type="supplementary-material" rid="pone.0248103.s001">S1 Table</xref>). Additionally, differential changes in the expression of 12 out of 47 proteins overlapped with insulin-induced changes compared to control samples (<xref rid="pone.0248103.t002" ref-type="table">Table 2</xref>) and 17 proteins were differentially expressed after metformin administration when compared to an hyperinsulinemic environment (CCND2, CD2, CD63, CD81, CDCP1, CTGF, F3, FGF2, GFAP, GUSB, HAVCR1, IRF4, PI3, PLAUR, PPIA, UBE2T, VTCN1). A total of 3 proteins were differentially expressed in all 3 considered groups (HGF, IL5, TFRC) (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1E</xref>).</p><table-wrap id="pone.0248103.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.t001</object-id><label>Table 1</label><caption><title>Changes in protein expression after metformin treatment and insulin supplementation.</title></caption><alternatives><graphic id="pone.0248103.t001g" xlink:href="pone.0248103.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" colspan="2" rowspan="1"><bold>proteins (15) affected by metformin treatment (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x02265;&#x000a0;0.5), but not hyperinsulinemia (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x0003c;&#x000a0;0.5)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">upregulated:</td><td align="left" rowspan="1" colspan="1">AKT3, BDNF, CCL8, CCL28, CXCL12, ITGA2B, MIF</td></tr><tr><td align="left" rowspan="1" colspan="1">downregulated:</td><td align="left" rowspan="1" colspan="1">ARVCF, CD3E, CD9, CD22, IL17A, KLK3, MKI67, RAD51C</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>proteins (15) with significantly differential expression due to metformin treatment (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x02265;&#x000a0;0.5 and <italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.05)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">upregulated:</td><td align="left" rowspan="1" colspan="1">AKT3, CTSL, GFAP, GUSB, IL5, PI3, TFRC</td></tr><tr><td align="left" rowspan="1" colspan="1">downregulated:</td><td align="left" rowspan="1" colspan="1">CCND2, CD63, CD81, IL1B, IL2, IL17A, IRF4, VTCN1</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>proteins (9) affected by hyperinsulinemia (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x02265;&#x000a0;0.5), but not metformin treatment (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x0003c;&#x000a0;0.5)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">upregulated:</td><td align="left" rowspan="1" colspan="1">CTSD, PRSS3, SPP1</td></tr><tr><td align="left" rowspan="1" colspan="1">downregulated:</td><td align="left" rowspan="1" colspan="1">CDH2, DKK3, FAF1, HBEGF, IGLC1, PGC</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>proteins (11) with significantly differential expression due to hyperinsulinemia (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x02265;&#x000a0;0.5 and <italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.05)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">upregulated:</td><td align="left" rowspan="1" colspan="1">AMFR, CEACAM8, MPP3, PLCG2, SORL1, SPP1, VEGFA, WNT2B</td></tr><tr><td align="left" rowspan="1" colspan="1">downregulated:</td><td align="left" rowspan="1" colspan="1">COL1A1, FAF1, IRS2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Compared to untreated control cells, metformin-treated cells differentially expressed 47 proteins, of which 15 were exclusively changed by the biguanide drug (and not hyperinsulinemia). Insulin-treated cells differentially expressed 40 proteins, of which 9 were exclusively changed by the pancreatic hormone (and not metformin).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0248103.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.t002</object-id><label>Table 2</label><caption><title>Changes in protein expression between metformin- and insulin-treated cells.</title></caption><alternatives><graphic id="pone.0248103.t002g" xlink:href="pone.0248103.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" colspan="2" rowspan="1"><bold>proteins (12) with differential expression compared to untreated controls (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x02265;&#x000a0;0.5) that were regulated by metformin and hyperinsulinemia in the same way</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">upregulated:</td><td align="left" rowspan="1" colspan="1">CD69, FCER2</td></tr><tr><td align="left" rowspan="1" colspan="1">downregulated:</td><td align="left" rowspan="1" colspan="1">COL1A1, EGFR, FLOT1, IL1B, IL2, IL15, IRS2, KDR, RP9, S100B</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>proteins (8) with significantly differential expression compared to untreated controls (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x02265;&#x000a0;0.5 and <italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.05) that were significantly higher expressed after metformin treatment compared to hyperinsulinemia</bold></td></tr><tr><td align="left" colspan="2" rowspan="1">CTSL, F3, GUSB, LGALS1, LGMN, NT5E, PI3, PLAUR</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>proteins (24) with significantly differential expression compared to untreated controls (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x02265;&#x000a0;0.5 and <italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.05) that were significantly higher expressed during hyperinsulinemia compared to metformin treatment</bold></td></tr><tr><td align="left" colspan="2" rowspan="1">AMFR, CCND2, CD63, CDCP1, CDH5, CEACAM8, EGF, ERBB3, ETS2, EZR, GDF15, GPX4, IRF4, MPP3, PLCG2, SELE, SIGLEC5, SORL1, SPP1, THBS1, TM9SF2, VEGFA, VTCN1, WNT2B</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>proteins (8) without differential expression compared to untreated controls (|log</bold><sub><bold>2</bold></sub><bold>FC|&#x000a0;&#x0003c;&#x000a0;0.5), but with significantly differential expression between metformin treatment and hyperinsulinemia</bold></td></tr><tr><td align="left" colspan="2" rowspan="1">ERBB3, ETS2, GDF15, GPX4, LGALS1, LGMN, NT5E, THBS1</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>A total of 44 proteins were differentially expressed between metformin and insulin-treated groups, of which only 12 proteins were regulated in the same way. The remaining 32 proteins were regulated in different ways by metformin and insulin, of which 8 proteins were significantly higher expressed after metformin administration, whereas 24 proteins were significantly more prominent during hyperinsulinemia. A total of 8 proteins were differentially expressed between both treatments groups without notable changes compared to the respective untreated control samples.</p></fn></table-wrap-foot></table-wrap><p>Compared to untreated control cells, insulin-treated cells differentially expressed 40 proteins (with |log<sub>2</sub>FC| &#x02265; 0.5 and/or adjusted <italic>p</italic> value &#x02264; 0.05), of which 9 proteins were exclusively changed by the pancreatic hormone and not metformin (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1E</xref> and <xref rid="pone.0248103.t001" ref-type="table">Table 1</xref>). A total of 11 out of 40 proteins met both of the above-mentioned criteria (log<sub>2</sub>FC| &#x02265; 0.5 and adjusted <italic>p</italic> value &#x02264; 0.05) in the insulin resistance model and thus were significantly differential expressed in comparison to untreated control samples (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1B</xref>, <xref rid="pone.0248103.t001" ref-type="table">Table 1</xref> and <xref ref-type="supplementary-material" rid="pone.0248103.s001">S1 Table</xref>). Additionally, 16 out of 40 proteins were differentially expressed due to insulin supplementation when compared to metformin-treated HEC-1A cells (ACVRL1, AMFR, CDH5, CEACAM8, CTGF, EGF, EZR, IL4, MPP3, PLCG2, SELE, SIGLEC5, SORL1, TM9SF2, VEGFA, WNT2B) (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1E</xref>).</p><p>Furthermore, 44 proteins were differentially expressed between the metformin- and insulin-treated groups (with |log<sub>2</sub>FC| &#x02265; 0.5 and/or adjusted <italic>p</italic> value &#x02264; 0.05), of which only 12 proteins were regulated by metformin and insulin in the same way (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1E</xref> and <xref rid="pone.0248103.t002" ref-type="table">Table 2</xref>). A total of 32 out of 44 proteins met both of the criteria (|log<sub>2</sub>FC| &#x02265; 0.5 and adjusted <italic>p</italic> value &#x02264; 0.05), of which 8 proteins were significantly higher expressed after metformin treatment, whereas 24 proteins were significantly more prominent in insulin-treated cells (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1C</xref>, <xref rid="pone.0248103.t002" ref-type="table">Table 2</xref> and <xref ref-type="supplementary-material" rid="pone.0248103.s001">S1 Table</xref>). A total of 8 out of 44 proteins were differentially expressed between both treatments groups without notable changes compared to the respective untreated control samples (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1E</xref> and <xref rid="pone.0248103.t002" ref-type="table">Table 2</xref>).</p><p>A total of 80 proteins were differentially expressed (|log<sub>2</sub>FC| &#x02265; 0.5 and/or an adjusted <italic>p</italic> value &#x02264; 0.05) under one of the tested conditions (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1E</xref>) and were plotted and further analyzed (<xref ref-type="fig" rid="pone.0248103.g002">Fig 2</xref>). A total of 17 proteins were significantly different from the control sample after metformin treatment (F3, PLAUR: |log<sub>2</sub>FC| &#x0003c; 0.5), whereas insulin significantly changed the expression of 15 proteins (EGF, EZR, TM9SF2: |log<sub>2</sub>FC| &#x0003c; 0.5). Of the 80 selected proteins, 34 proteins displayed a significantly different expression between both treatment groups (GFAP, TFRC: |log<sub>2</sub>FC| &#x0003c; 0.5). The results of the antibody microarray analysis have been confirmed for selected proteins, namely IL2 (ELISA) and COL1A1 (western blot analysis) (<xref ref-type="supplementary-material" rid="pone.0248103.s002">S1 Fig</xref>).</p><fig id="pone.0248103.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.g002</object-id><label>Fig 2</label><caption><title>Expression of selected proteins in endometrial cancer cells after treatment with metformin or insulin.</title><p>Differences in protein abundance between sample groups are presented as log<sub>2</sub>-fold changes (log<sub>2</sub>FC). Proteins were selected based on the following criteria: |log<sub>2</sub>FC| &#x02265; 0.5 and/or adjusted <italic>p</italic> value &#x02264; 0.05. Proteins were defined as significantly differential for |log<sub>2</sub>FC| &#x0003e; 0.5 and adjusted <italic>p</italic> values &#x0003c; 0.05; *<italic>p</italic> &#x02264; 0.05, **<italic>p</italic> &#x02264; 0.01, ***<italic>p</italic> &#x02264; 0.001, ****<italic>p</italic> &#x02264; 0.0001 (metformin/insulin vs. control); <sup>#</sup><italic>p</italic> &#x02264; 0.05, <sup>##</sup><italic>p</italic> &#x02264; 0.01, <sup>###</sup><italic>p</italic> &#x02264; 0.001, <sup>####</sup><italic>p</italic> &#x02264; 0.0001 (metformin vs. insulin).</p></caption><graphic xlink:href="pone.0248103.g002"/></fig><p>The 80 selected proteins were subjected to STRING analysis and protein networks were generated. Characteristic biological processes and molecular functions that were affected by the treatments were identified and proteins were assigned to clusters (<xref ref-type="fig" rid="pone.0248103.g003">Fig 3</xref> and <xref ref-type="supplementary-material" rid="pone.0248103.s001">S1 Table</xref>). A total of 53 proteins were allocated to four different clusters of biological processes, of which 12 proteins were summarized in a subset related to cell population proliferation (e.g. CD81, MKI67, FGF2) (<xref ref-type="fig" rid="pone.0248103.g003">Fig 3A</xref>). Another two clusters contained 20 (e.g. CD63, CDH5, CEACAM8) and 23 proteins (e.g. CDH2, COL1A1, VEGFA) that were associated with cell adhesion and cell migration, respectively. A total of 29 proteins were related to immune response (e.g. CD3E, IL2, IL4). The remaining 27 proteins are not directly related to any of the above-mentioned biological processes.</p><fig id="pone.0248103.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.g003</object-id><label>Fig 3</label><caption><title>Network of proteins affected by metformin and insulin supplementation.</title><p>Proteins that displayed a |log<sub>2</sub>FC| &#x02265; 0.5 and/or an adjusted <italic>p</italic> value &#x02264; 0.05 (total number: 80) were subjected to STRING analysis and protein clusters for biological processes (<bold>A</bold>, 53 proteins) or molecular functions (<bold>B</bold>, 31 proteins) were identified with the GO database. (<bold>A</bold>) Biological processes were divided into subsets related to cell population proliferation (red, 12 proteins), cell adhesion (blue, 20 proteins), cell migration (green, 23 proteins), and immune response (yellow, 29 proteins). A total of 27 proteins could not be assigned to any of the four biological processes (not shown). (<bold>B</bold>) Identified molecular functions included growth factor (red, 12 proteins), cytokine (blue, 14 proteins), chemokine (green, 3 proteins), and signal receptor activity (yellow, 13 proteins). A total of 50 proteins could not be assigned to any of the four molecular functions (not shown).</p></caption><graphic xlink:href="pone.0248103.g003"/></fig><p>Additionally, 31 proteins were assigned to four different clusters related to molecular functions, of which 12 proteins were summarized in a subset characterized by growth factor activity (e.g. CTGF, EGF, HGF) (<xref ref-type="fig" rid="pone.0248103.g003">Fig 3B</xref>). Another two clusters contained 14 (e.g. IL1B, IL2, IL17A) and 3 proteins (CCL8, CCL28, CXCL12) that were associated with cytokine and chemokine activity, respectively. A total of 13 proteins showed signal receptor activity (e.g. EGFR, ERBB3, KDR). The remaining 50 proteins could not be assigned to any of the above-mentioned molecular functions.</p><p>A more detailed pathway analysis of differentially expressed proteins distinguished between effects caused by either metformin or insulin compared to untreated HEC-1A control cells (metformin vs. control: 47 proteins; insulin vs. control: 40 proteins) and was carried out with the DAVID database (Tables <xref rid="pone.0248103.t003" ref-type="table">3</xref> and <xref rid="pone.0248103.t004" ref-type="table">4</xref>). GO and KEGG annotations were considered relevant, if the following criteria were met: protein counts &#x02265; 10% (metformin vs. control: &#x02265; 5 counts; insulin vs. control: &#x02265; 4 counts) and <italic>p</italic> values &#x02264; 0.001 (from DAVID analysis).</p><table-wrap id="pone.0248103.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.t003</object-id><label>Table 3</label><caption><title>Pathway analysis for differentially expressed proteins that were affected by metformin compared to untreated HEC-1A control cells.</title></caption><alternatives><graphic id="pone.0248103.t003g" xlink:href="pone.0248103.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Identifier</th><th align="justify" rowspan="1" colspan="1">Description</th><th align="center" rowspan="1" colspan="1">Counts</th><th align="center" rowspan="1" colspan="1"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><bold>Cellular Component</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005615</td><td align="left" rowspan="1" colspan="1">extracellular space</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">1.74&#x000d7;10<sup>&#x02212;12</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005576</td><td align="left" rowspan="1" colspan="1">extracellular region</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">3.47&#x000d7;10<sup>&#x02212;9</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0070062</td><td align="left" rowspan="1" colspan="1">extracellular exosome</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">8.36&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005887</td><td align="left" rowspan="1" colspan="1">integral component of plasma membrane</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">6.27&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0009897</td><td align="left" rowspan="1" colspan="1">external side of plasma membrane</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">2.60&#x000d7;10<sup>&#x02212;9</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0009986</td><td align="left" rowspan="1" colspan="1">cell surface</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">3.87&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005925</td><td align="left" rowspan="1" colspan="1">focal adhesion</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">4.26&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Molecular Function</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005515</td><td align="left" rowspan="1" colspan="1">protein binding</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">2.20&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005125</td><td align="left" rowspan="1" colspan="1">cytokine activity</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">7.82&#x000d7;10<sup>&#x02212;6</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0008083</td><td align="left" rowspan="1" colspan="1">growth factor activity</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">7.63&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005178</td><td align="left" rowspan="1" colspan="1">integrin binding</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1.89&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005088</td><td align="left" rowspan="1" colspan="1">Ras guanyl-nucleotide exchange factor activity</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">2.67&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Biological Process</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0008284</td><td align="left" rowspan="1" colspan="1">positive regulation of cell proliferation</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">3.29&#x000d7;10<sup>&#x02212;6</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0006955</td><td align="left" rowspan="1" colspan="1">immune response</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">1.40&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0007155</td><td align="left" rowspan="1" colspan="1">cell adhesion</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">2.01&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0007166</td><td align="left" rowspan="1" colspan="1">cell surface receptor signaling pathway</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">8.53&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0006954</td><td align="left" rowspan="1" colspan="1">inflammatory response</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">4.92&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0030890</td><td align="left" rowspan="1" colspan="1">positive regulation of B cell proliferation</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">5.91&#x000d7;10<sup>&#x02212;8</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0001934</td><td align="left" rowspan="1" colspan="1">positive regulation of protein phosphorylation</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">2.19&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0030335</td><td align="left" rowspan="1" colspan="1">positive regulation of cell migration</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1.28&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0007267</td><td align="left" rowspan="1" colspan="1">cell-cell signaling</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">5.68&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0000165</td><td align="left" rowspan="1" colspan="1">MAPK cascade</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6.53&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0042102</td><td align="left" rowspan="1" colspan="1">positive regulation of T cell proliferation</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1.97&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0050731</td><td align="left" rowspan="1" colspan="1">positive regulation of peptidyl-tyrosine phosphorylation</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">6.76&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0045766</td><td align="left" rowspan="1" colspan="1">positive regulation of angiogenesis</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">2.50&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0006935</td><td align="left" rowspan="1" colspan="1">Chemotaxis</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.14&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>KEGG Pathway</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa04640</td><td align="left" rowspan="1" colspan="1">hematopoietic cell lineage</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">6.42&#x000d7;10<sup>&#x02212;9</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa04060</td><td align="left" rowspan="1" colspan="1">cytokine-cytokine receptor interaction</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">5.10&#x000d7;10<sup>&#x02212;6</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa04151</td><td align="left" rowspan="1" colspan="1">PI3K/AKT signaling pathway</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">1.45&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa05205</td><td align="left" rowspan="1" colspan="1">proteoglycans in cancer</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">3.25&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa04510</td><td align="left" rowspan="1" colspan="1">focal adhesion</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">3.38&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa04672</td><td align="left" rowspan="1" colspan="1">intestinal immune network for IgA production</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1.12&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa05323</td><td align="left" rowspan="1" colspan="1">rheumatoid arthritis</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">9.14&#x000d7;10<sup>&#x02212;4</sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>The DAVID database was used for pathway analysis and GO and KEGG pathway identifiers are shown for protein counts &#x02265; 10% (metformin vs. control: &#x02265; 5 counts) of the total number of 47 analyzed proteins with <italic>p</italic> values &#x02264; 0.001 (from DAVID analysis).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0248103.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.t004</object-id><label>Table 4</label><caption><title>Pathway analysis for differentially expressed proteins that were affected by hyperinsulinemia compared to untreated HEC-1A control cells.</title></caption><alternatives><graphic id="pone.0248103.t004g" xlink:href="pone.0248103.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Identifier</th><th align="justify" rowspan="1" colspan="1">Description</th><th align="justify" rowspan="1" colspan="1">Counts</th><th align="justify" rowspan="1" colspan="1"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><bold>Cellular Component</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005615</td><td align="left" rowspan="1" colspan="1">extracellular space</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">1.96&#x000d7;10<sup>&#x02212;18</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005576</td><td align="left" rowspan="1" colspan="1">extracellular region</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">5.88&#x000d7;10<sup>&#x02212;11</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0070062</td><td align="left" rowspan="1" colspan="1">extracellular exosome</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">2.88&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005887</td><td align="left" rowspan="1" colspan="1">integral component of plasma membrane</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">4.86&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0048471</td><td align="left" rowspan="1" colspan="1">perinuclear region of cytoplasm</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">3.44&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005768</td><td align="left" rowspan="1" colspan="1">Endosome</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">3.63&#x000d7;10<sup>&#x02212;7</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0009986</td><td align="left" rowspan="1" colspan="1">cell surface</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">8.27&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0009897</td><td align="left" rowspan="1" colspan="1">external side of plasma membrane</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">7.63&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0016323</td><td align="left" rowspan="1" colspan="1">basolateral plasma membrane</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5.23&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0045121</td><td align="left" rowspan="1" colspan="1">membrane raft</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">8.66&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Molecular Function</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005515</td><td align="left" rowspan="1" colspan="1">protein binding</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">3.77&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0008083</td><td align="left" rowspan="1" colspan="1">growth factor activity</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">4.35&#x000d7;10<sup>&#x02212;8</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005125</td><td align="left" rowspan="1" colspan="1">cytokine activity</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">1.77&#x000d7;10<sup>&#x02212;6</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005088</td><td align="left" rowspan="1" colspan="1">Ras guanyl-nucleotide exchange factor activity</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">4.28&#x000d7;10<sup>&#x02212;6</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0005178</td><td align="left" rowspan="1" colspan="1">protein tyrosine kinase activity</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1.78&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Biological Process</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0008284</td><td align="left" rowspan="1" colspan="1">positive regulation of cell proliferation</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">5.79&#x000d7;10<sup>&#x02212;8</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0007165</td><td align="left" rowspan="1" colspan="1">signal transduction</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">1.90&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0030335</td><td align="left" rowspan="1" colspan="1">positive regulation of cell migration</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">3.29&#x000d7;10<sup>&#x02212;6</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0000165</td><td align="left" rowspan="1" colspan="1">MAPK cascade</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">2.47&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0006955</td><td align="left" rowspan="1" colspan="1">immune response</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">3.35&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0007155</td><td align="left" rowspan="1" colspan="1">cell adhesion</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">5.30&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0030890</td><td align="left" rowspan="1" colspan="1">positive regulation of B cell proliferation</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1.73&#x000d7;10<sup>&#x02212;6</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0048015</td><td align="left" rowspan="1" colspan="1">phosphatidylinositol (PI)-mediated signaling</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">9.39&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0045766</td><td align="left" rowspan="1" colspan="1">positive regulation of angiogenesis</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1.29&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0001934</td><td align="left" rowspan="1" colspan="1">positive regulation of protein phosphorylation</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1.89&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GO:0018108</td><td align="left" rowspan="1" colspan="1">peptidyl-tyrosine phosphorylation</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.84&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>KEGG Pathway</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa04151</td><td align="left" rowspan="1" colspan="1">PI3K/AKT signaling pathway</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">2.60&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa05205</td><td align="left" rowspan="1" colspan="1">proteoglycans in cancer</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">6.50&#x000d7;10<sup>&#x02212;6</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa04510</td><td align="left" rowspan="1" colspan="1">focal adhesion</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">9.35&#x000d7;10<sup>&#x02212;5</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa04640</td><td align="left" rowspan="1" colspan="1">hematopoietic cell lineage</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">2.89&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">hsa04066</td><td align="left" rowspan="1" colspan="1">HIF1 signaling</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4.21&#x000d7;10<sup>&#x02212;4</sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>The DAVID database was used for pathway analysis and GO and KEGG pathway identifiers are shown for protein counts &#x02265; 10% (insulin vs. control: &#x02265; 4 counts) of the total number of 40 analyzed proteins with <italic>p</italic> values &#x02264; 0.001 (from DAVID analysis).</p></fn></table-wrap-foot></table-wrap><p>Analysis of cellular components after metformin treatment revealed that most regulated proteins belonged to extracellular space/regions (19&#x02013;22) and were mainly constituents of the plasma membrane (8&#x02013;12), of which some were related to focal adhesion (7) (<xref rid="pone.0248103.t003" ref-type="table">Table 3</xref>). Molecular functions of the affected proteins included protein binding (37), growth-related functions (6&#x02013;7), and adhesion (5). The biological processes of the regulated proteins were related to cell proliferation (10), particularly of B and T cells (5&#x02013;6), and with involvement of the MAPK cascade (6), cell adhesion, migration as well as angiogenesis (5&#x02013;8), and immune (9) or inflammatory (7) responses. Furthermore, KEGG pathway analysis revealed a link to PI3K/AKT signaling (9), a pathway involved in quiescence, proliferation, and cancer. Cytokine-cytokine receptor interactions (9), focal adhesion (7), cancer-related components of the extracellular matrix, so called proteoglycans (8), and a link to hematopoiesis (9) were also identified as pathways that were targeted by metformin administration.</p><p>Likewise, analysis of cellular components after insulin treatment revealed that most regulated proteins belonged to extracellular space/regions (16&#x02013;25) and were mainly constituents of the plasma membrane (5&#x02013;11) or endosomes (8) (<xref rid="pone.0248103.t004" ref-type="table">Table 4</xref>). Molecular functions of the affected proteins included protein binding (30), growth-related functions (7&#x02013;8), and adhesion (5). The biological processes of the regulated proteins were related to cell proliferation (11), particularly of B cells (5), and with involvement of the MAPK cascade (7) and phosphatidylinositol (PI) signaling (5), cell adhesion, migration as well as angiogenesis (5&#x02013;7), signal transduction (11), and immune responses (7). Furthermore, KEGG pathway analysis revealed a link to PI3K/AKT signaling (9), proteoglycans (8), focal adhesion (7), hematopoiesis (5), and hypoxia-inducible factor 1 (HIF1) signaling in a hyperinsulinemic environment.</p></sec><sec sec-type="conclusions" id="sec008"><title>4. Discussion</title><p>Besides its effects on glucose metabolism, the insulin-sensitizing drug metformin displayed anti-cancer effects in various cancer types [<xref rid="pone.0248103.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0248103.ref018" ref-type="bibr">18</xref>], including EC [<xref rid="pone.0248103.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0248103.ref021" ref-type="bibr">21</xref>]. Metabolic diseases like type II diabetes mellitus and obesity, together with increased unopposed estrogen levels, as seen in anovulatory women with PCOS as well as in women with prolonged reproductive phases including early menarche and late menopause, are known risk factors for EC development [<xref rid="pone.0248103.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0248103.ref011" ref-type="bibr">11</xref>]. Metformin sensitizes the body to insulin effects and decreases hepatic gluconeogenesis <italic>in vivo</italic>, consequently leading to a reduction and thus to a normalization of blood glucose levels [<xref rid="pone.0248103.ref057" ref-type="bibr">57</xref>, <xref rid="pone.0248103.ref058" ref-type="bibr">58</xref>]. In the present study, the direct effects of metformin on protein expression in the human EC cell line HEC-1A were investigated using an affinity proteomic approach. Insulin treatment was incorporated into the study in order to implement a model for insulin resistance, defined as normoglycemia reached by hyperinsulinemia, a condition often observed in obese and prediabetic patients [<xref rid="pone.0248103.ref043" ref-type="bibr">43</xref>]. Additionally, cells were treated in the presence of E2 to mimic increased estrogen levels, a common risk factor for EC development. Protein lysates of HEC-1A cells were collected 7 d after repeated administration of 0.5 mmol/L metformin or 100 ng/mL insulin and subjected to the scioDiscover antibody microarray targeting 1,300 different proteins. The aim of this study was to perform a proteomic screening after metformin as well as insulin treatment and to identify changes in protein expression that potentially contribute to the anti-cancer effects and the mechanism of action of the biguanide drug in EC.</p><p>Protein expression was compared to untreated controls and between metformin treatment and insulin supplementation (<xref ref-type="fig" rid="pone.0248103.g001">Fig 1</xref>). A total of 80 differentially expressed proteins were selected for further analysis based on most prominent changes (<xref ref-type="fig" rid="pone.0248103.g002">Fig 2</xref>). These proteins were subjected to STRING analysis for the generation of protein networks (<xref ref-type="fig" rid="pone.0248103.g003">Fig 3</xref>). Clusters of proteins were detected and proteins were assigned to four different biological processes including cell population proliferation, cell adhesion, cell migration and immune response (<xref ref-type="fig" rid="pone.0248103.g003">Fig 3A</xref>). Metformin has been found to act on these pathways in several studies before [<xref rid="pone.0248103.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0248103.ref059" ref-type="bibr">59</xref>&#x02013;<xref rid="pone.0248103.ref061" ref-type="bibr">61</xref>]. Molecular functions of the affected proteins included growth factor, cytokine, chemokine, and signal receptor activities (<xref ref-type="fig" rid="pone.0248103.g003">Fig 3B</xref>).</p><p>A more detailed pathway analysis (GO and KEGG) of differentially expressed proteins discriminated between the effects caused by either metformin or insulin. The generated data from the DAVID database revealed that both metformin treatment and hyperinsulinemia targeted similar pathways (Tables <xref rid="pone.0248103.t003" ref-type="table">3</xref> and <xref rid="pone.0248103.t004" ref-type="table">4</xref>). However, the regulated proteins varied among the treatment groups compared to untreated controls. Metformin and hyperinsulinemia changed the expression of extracellular proteins (e.g. metformin: CTSL, EGFR, IL5, KLK3; insulin: IL4, IL15, PGC, SORL1). Molecular functions of differentially regulated proteins were mainly related to binding, growth factor and immune-related cytokine activities (e.g. metformin: EGFR, IL1B, IL5, IL17A; insulin: EGFR, IL4, IL5, VEGFA). Affected biological processes included proliferation, adhesion, migration, angiogenesis and immune responses (e.g. metformin: CD3E, IL5, IL17A, TFRC; insulin: CEACAM8, CTGF, EGFR, IL4, IRS2). KEGG analysis identified adhesion, hematopoiesis and cancer-related proteoglycans as affected pathways (e.g. metformin: CD9, CTSL, IL5, HGF; insulin: EGF, EZR, PLCG2, TFRC). Furthermore, changes of proteins involved in PI3K/AKT signaling were detected (e.g. metformin: AKT3, CCND2, EGFR, FGF2; insulin: COL1A1, IL4, EGFR, VEGFA), a pathway that is a well-known target of metformin [<xref rid="pone.0248103.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0248103.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0248103.ref059" ref-type="bibr">59</xref>, <xref rid="pone.0248103.ref062" ref-type="bibr">62</xref>, <xref rid="pone.0248103.ref063" ref-type="bibr">63</xref>] and insulin [<xref rid="pone.0248103.ref064" ref-type="bibr">64</xref>&#x02013;<xref rid="pone.0248103.ref066" ref-type="bibr">66</xref>].</p><p>Some proteins were regulated by metformin in a favorable way regarding tumor suppression and growth inhibition compared to untreated EC cells (<xref rid="pone.0248103.t005" ref-type="table">Table 5</xref>), while they were not changed in regards to hyperinsulinemia. The following proteins were significantly downregulated by metformin, while no significant changes were detected in a hyperinsulinemic environment compared to the control: cyclin D2 (CCND2), cluster of differentiation 63 (CD63), CD81, interleukin-17A (IL17A), interferon regulatory factor 4 (IRF4), and V-set domain containing T cell activation inhibitor 1 (VTCN1, B7-H4). Downregulation of CCND2, a protein known to cause growth arrest in the G<sub>1</sub> cell cycle phase, and CD81, a protein relevant for membrane organization, protein trafficking, cellular fusion and cell-cell interactions, contributes to a decreased proliferation, tumor progression, migration, and invasion [<xref rid="pone.0248103.ref067" ref-type="bibr">67</xref>&#x02013;<xref rid="pone.0248103.ref070" ref-type="bibr">70</xref>]. Downregulation of CD63, a tetraspanin involved in the regulation of membrane protein trafficking, leukocyte recruitment and adhesion, was found to reduce apoptosis inhibition as well as cell survival [<xref rid="pone.0248103.ref071" ref-type="bibr">71</xref>], and to suppress vascular endothelial growth factor (VEGF) signaling as well as related angiogenesis [<xref rid="pone.0248103.ref072" ref-type="bibr">72</xref>]. In addition, metformin reduced the expression of several proteins related to immune responses, including VTCN1, a B7 family member involved in immune regulation, as well as IRF4, a regulator of lymphocyte growth and differentiation, leading to decreased tumor cell proliferation and metastasis [<xref rid="pone.0248103.ref073" ref-type="bibr">73</xref>&#x02013;<xref rid="pone.0248103.ref075" ref-type="bibr">75</xref>]. Furthermore, IL17A is involved in immune responses and inflammation [<xref rid="pone.0248103.ref076" ref-type="bibr">76</xref>], but also promotes migration and invasion in cancer cells [<xref rid="pone.0248103.ref077" ref-type="bibr">77</xref>]. Therefore, a metformin-induced downregulation of the cytokine has the potential to inhibit migration and invasion. Ambiguous results were obtained after metformin-induced downregulation of IL1B and IL2. IL1B not only activates antigen-presenting cells, thereby initiating an adaptive anti-tumor response, but also promotes tumor growth, metastasis as well as angiogenesis upon activation by tumor-infiltrating macrophages. Therefore, downregulation of IL1B may decrease carcinogenesis and metastasis, but may also be able to block adaptive anti-tumor responses. Hence, IL1B-blocking drugs such as anakinra and canakinumab are currently investigated as cancer therapeutics [<xref rid="pone.0248103.ref078" ref-type="bibr">78</xref>, <xref rid="pone.0248103.ref079" ref-type="bibr">79</xref>]. The cytokine IL2 is important for growth of T cells and natural killer cells, despite its regulatory effect in cell cycle progression and tumor cell growth [<xref rid="pone.0248103.ref080" ref-type="bibr">80</xref>]. On the one hand, downregulation of IL2 has been associated with decreased proliferation and carcinogenesis. On the other hand, no survival benefits were observed after administration of IL2 in metastatic renal cancer and melanoma, although the cytokine had led to a regression of metastatic tumors [<xref rid="pone.0248103.ref081" ref-type="bibr">81</xref>]. Therefore, the consequences of metformin treatment and hyperinsulinemia for the cellular fate are difficult to assess for these two interleukins and need to be further investigated to allow for clear conclusions.</p><table-wrap id="pone.0248103.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.t005</object-id><label>Table 5</label><caption><title>Favorable and unfavorable changes in the expression of significantly differential expressed proteins after metformin treatment.</title></caption><alternatives><graphic id="pone.0248103.t005g" xlink:href="pone.0248103.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" colspan="3" rowspan="1">significantly differential expressed proteins after metformin administration</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">favorable regulation:</td><td align="left" rowspan="1" colspan="1">AKT3, CCND2, CD63, CD81, GFAP, IL5, IL17A, IRF4, PI3, VTCN1</td><td align="left" rowspan="2" colspan="1">(IL1B, IL2)</td></tr><tr><td align="left" rowspan="1" colspan="1">unfavorable regulation:</td><td align="left" rowspan="1" colspan="1">CTSL, GUSB, TFRC</td></tr></tbody></table></alternatives></table-wrap><p>A significant protein upregulation compared to the untreated control was induced by metformin, but not by hyperinsulinemia, for immune regulatory factors such as IL5 and peptidase inhibitor 3 (PI3, elafin (ELAF)). IL5 is involved in the regulation and recruiting of eosinophils, which are critical for the suppression of tumor metastasis [<xref rid="pone.0248103.ref082" ref-type="bibr">82</xref>, <xref rid="pone.0248103.ref083" ref-type="bibr">83</xref>], while an upregulation of PI3 counterbalances the mitogenic effects of the PI3 substrate elastase from activated neutrophils in the tumor microenvironment, thus reducing proliferation, tumorigenesis and migration [<xref rid="pone.0248103.ref084" ref-type="bibr">84</xref>, <xref rid="pone.0248103.ref085" ref-type="bibr">85</xref>] as well as increasing apoptosis in tumor cells [<xref rid="pone.0248103.ref086" ref-type="bibr">86</xref>]. In addition, the overexpression of glial fibrillary acidic protein (GFAP), a component of intermediate filaments and hence a part of the cytoskeleton, is believed to decrease cell proliferation and tumor growth [<xref rid="pone.0248103.ref087" ref-type="bibr">87</xref>]. Similarly, upregulation of AKT3, an isoform of AKT and a major mediator of the cell cycle-regulating PI3K/AKT/mTOR signaling pathway, may decrease the motility and migration potential of cells [<xref rid="pone.0248103.ref088" ref-type="bibr">88</xref>, <xref rid="pone.0248103.ref089" ref-type="bibr">89</xref>]. All the changes discussed above may be involved in a reduction of tumor progression and metastasis when metformin treatment is applied.</p><p>Unfavorable effects of metformin treatment may involve the upregulation of beta-glucuronidase (GUSB, BGLR), cathepsin L (CTSL, CATL1), and transferrin receptor 1 (TFRC, TFR1) (<xref rid="pone.0248103.t005" ref-type="table">Table 5</xref>). GUSB expression has been correlated with increased invasion of tumor cells [<xref rid="pone.0248103.ref090" ref-type="bibr">90</xref>, <xref rid="pone.0248103.ref091" ref-type="bibr">91</xref>], however, it remains unclear, whether an increased expression of GUSB is directly involved in tumor progression or is just upregulated during the process and rather serves as a marker for invasiveness [<xref rid="pone.0248103.ref090" ref-type="bibr">90</xref>]. Upregulation of CTSL leads to an increased degradation of components of the extracellular matrix (ECM), namely collagen and elastin, resulting in enhanced invasion and metastasis [<xref rid="pone.0248103.ref092" ref-type="bibr">92</xref>, <xref rid="pone.0248103.ref093" ref-type="bibr">93</xref>]. TFRC is involved in the uptake of the iron-transporting glycoprotein transferrin into cells and helps meet the high demands for iron in tumor cells [<xref rid="pone.0248103.ref094" ref-type="bibr">94</xref>]. Hyperinsulinemia, however, did not change GUSB, slightly decreased CTSL expression and increased TFRC levels, all of these changes being significantly different from the metformin effects.</p><p>The following proteins were changed in a favorable way regarding tumor suppression and inhibition of invasiveness particularly under the influence of insulin (<xref rid="pone.0248103.t006" ref-type="table">Table 6</xref>) and to a lesser extent by metformin in comparison to untreated control cells: collagen type I alpha 1 chain (COL1A1), and insulin receptor substrate 2 (IRS2). COL1A1, the major component of collagen type I, which, in turn, constitutes the main structural ECM protein, promotes cell migration and metastasis [<xref rid="pone.0248103.ref095" ref-type="bibr">95</xref>, <xref rid="pone.0248103.ref096" ref-type="bibr">96</xref>]. Thus, downregulation of the ECM component, as found to be induced by both insulin and metformin in the present study, is considered as a desired effect. IRS2, a cytoplasmic adaptor protein, mediates the effects of insulin as well as IGF1 and therefore plays a role in growth-promoting IGF1 receptor (IGF1R) signaling. Overexpression is associated with increased glucose metabolism and tumor invasion as well as decreased overall survival and disease progression in patients [<xref rid="pone.0248103.ref097" ref-type="bibr">97</xref>, <xref rid="pone.0248103.ref098" ref-type="bibr">98</xref>]. Therefore, the downregulation of IRS2 by hyperinsulinemia lowered tumor invasion and metastasis in the present study, which has also been proven in an obese and diabetic mouse model [<xref rid="pone.0248103.ref099" ref-type="bibr">99</xref>, <xref rid="pone.0248103.ref100" ref-type="bibr">100</xref>]. Ambiguous results were obtained for carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) that was expressed in higher amounts after insulin supplementation. CEACAM8, a cell adhesion molecule expressed on the surface of neutrophilic granulocytes, has been associated with poor prognosis and decreased survival in patients [<xref rid="pone.0248103.ref101" ref-type="bibr">101</xref>, <xref rid="pone.0248103.ref102" ref-type="bibr">102</xref>]. However, when bound to CEACAM6, upregulation of the CEACAM6/8 complex has been related to inhibition of vascular invasion and cell proliferation [<xref rid="pone.0248103.ref103" ref-type="bibr">103</xref>]. Little is known about the role of CEACAM8 in cancer [<xref rid="pone.0248103.ref102" ref-type="bibr">102</xref>], making it hard to assess the consequences of an insulin-induced CEACAM8 upregulation.</p><table-wrap id="pone.0248103.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.t006</object-id><label>Table 6</label><caption><title>Favorable and unfavorable changes in the expression of significantly differential expressed proteins during hyperinsulinemia.</title></caption><alternatives><graphic id="pone.0248103.t006g" xlink:href="pone.0248103.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" colspan="3" rowspan="1">significantly differential expressed proteins after insulin supplementation</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">favorable regulation:</td><td align="left" rowspan="1" colspan="1">COL1A1, IRS2</td><td align="center" rowspan="2" colspan="1">(CEACAM8)</td></tr><tr><td align="left" rowspan="1" colspan="1">unfavorable regulation:</td><td align="left" rowspan="1" colspan="1">AMFR, FAF1, MPP3, PLCG2, SORL1, SPP1, VEGFA, WNT2B</td></tr></tbody></table></alternatives></table-wrap><p>Besides the above-mentioned helpful effects observed in a hyperinsulinemic environment, elevated insulin levels also promoted a series of unfavorable changes (<xref rid="pone.0248103.t006" ref-type="table">Table 6</xref>) in EC cell protein expression, including the upregulation of autocrine motility factor receptor (AMFR), FAS-associated factor 1 (FAF1), membrane palmitoylated protein 3 (MPP3), enzyme 1-phosphatidylinositol-4,5-bisphosphate (PIP<sub>2</sub>) phosphodiesterase gamma-2 (PLCG2, phospholipase C&#x003b3;2), sortilin-related receptor 1 (SORL1), secreted phosphoprotein 1 (SPP1, osteopontin (OSTP)), VEGFA, and wingless-type MMTV integration site family member 2B (WNT2B). AMFR, a cell surface receptor for AMF, is involved in many processes including cell motility, and AMFR upregulation has been related to enhanced tumor invasion and migration [<xref rid="pone.0248103.ref104" ref-type="bibr">104</xref>, <xref rid="pone.0248103.ref105" ref-type="bibr">105</xref>]. WNT2B is involved in different cellular processes, including tumorigenesis, and WNT2B overexpression has been correlated with cancer progression and metastasis [<xref rid="pone.0248103.ref106" ref-type="bibr">106</xref>&#x02013;<xref rid="pone.0248103.ref108" ref-type="bibr">108</xref>]. Likewise, upregulation of MPP3, a membrane protein involved in cytoskeleton organization and regulation of cell proliferation, signal transduction, and intracellular tight junctions has been associated with enhanced cell migration and invasion [<xref rid="pone.0248103.ref109" ref-type="bibr">109</xref>]. PLCG2 catalyzes the hydrolysis of PIP<sub>2</sub> to form diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP<sub>3</sub>), being important 2<sup>nd</sup> messenger molecules that activate protein kinase C (PKC). PKC, in turn, is involved in signal transduction related to proliferation, differentiation, growth, and motility, among others [<xref rid="pone.0248103.ref110" ref-type="bibr">110</xref>, <xref rid="pone.0248103.ref111" ref-type="bibr">111</xref>]. Downregulation of PLCG2 led to decreased cellular viability and proliferation in an <italic>in vitro</italic> model [<xref rid="pone.0248103.ref112" ref-type="bibr">112</xref>], and therefore it is likely that a hyperinsulinemia-mediated PLCG2 upregulation promoted cell proliferation. Overexpression of SPP1, a protein involved in ECM adhesion during wound healing, is also associated with cancer progression, metastasis, and apoptosis inhibition [<xref rid="pone.0248103.ref113" ref-type="bibr">113</xref>, <xref rid="pone.0248103.ref114" ref-type="bibr">114</xref>], just like an upregulation of the transmembrane sorting protein SORL1 that promotes cell proliferation in cancer cells [<xref rid="pone.0248103.ref115" ref-type="bibr">115</xref>]. VEGFA mediates angiogenesis and vasculogenesis by regulation of endothelial cells and acts as a pro-survival factor of endothelial cells during tumor angiogenesis [<xref rid="pone.0248103.ref116" ref-type="bibr">116</xref>]. VEGFA overexpression, as seen after insulin supplementation in the present study, increased angiogenesis [<xref rid="pone.0248103.ref116" ref-type="bibr">116</xref>], while downregulation of VEGFA was not only found to inhibit cell proliferation, migration as well as invasion, but also to promote apoptosis [<xref rid="pone.0248103.ref117" ref-type="bibr">117</xref>]. Another unfavorable effect of hyperinsulinemia was identified by a downregulation of FAF1 in the present study, which was found to increase tumorigenesis [<xref rid="pone.0248103.ref118" ref-type="bibr">118</xref>], as FAF1 plays a role in various biological processes including apoptosis [<xref rid="pone.0248103.ref119" ref-type="bibr">119</xref>]. As metformin reduces peripheral hyperinsulinemia <italic>in vivo</italic>, the drug might be able to counteract the observed negative insulin effects when administered to patients with high levels of the pancreatic hormone. In addition, metformin acted on the expression of the discussed proteins in the opposite, more favorable way in the present study.</p><p>Several proteins have been expressed significantly different during metformin treatment and hyperinsulinemia, of which AMFR, CCND2, CD63, CEACAM8, CTSL, GFAP, GUSB, IRF4, PI3, PLCG2, SORL1, TFRC, VEGFA, VTCN1, and WNT2B have already been discussed above. Further proteins, that did not show high changes compared to untreated control samples (|log<sub>2</sub>FC| &#x0003c; 0.5), but displayed highly significant differences (<italic>p</italic> &#x02264; 0.001) among both treatments will now be discussed in more detail (<xref rid="pone.0248103.t007" ref-type="table">Table 7</xref>). Changes in protein expression by metformin treatment displayed advantages over a hyperinsulinemic environment for the following proteins: erythroblastic oncogene B2 receptor tyrosine kinase 3 (ERBB3, human epidermal growth factor receptor 3 (HER3)), ezrin (EZR), and transmembrane 9 superfamily member 2 (TM9SF2). ERBB3 is a member of the epidermal growth factor receptor (EGFR) family and is directly involved in the pro-proliferative PI3K signaling pathway [<xref rid="pone.0248103.ref120" ref-type="bibr">120</xref>]. EZR is responsible for the linkage of the plasma membrane to the actin cytoskeleton and plays a key role in adhesion and migration [<xref rid="pone.0248103.ref121" ref-type="bibr">121</xref>, <xref rid="pone.0248103.ref122" ref-type="bibr">122</xref>]. Little is known about the functions of TM9SF2 to date, but it is proposed to act as a channel or transporter [<xref rid="pone.0248103.ref123" ref-type="bibr">123</xref>]. Overexpression of ERBB3, EZR, and TM9SF2 has been associated with cancer progression, increased proliferation and metastasis or poor survival [<xref rid="pone.0248103.ref120" ref-type="bibr">120</xref>&#x02013;<xref rid="pone.0248103.ref122" ref-type="bibr">122</xref>, <xref rid="pone.0248103.ref124" ref-type="bibr">124</xref>, <xref rid="pone.0248103.ref125" ref-type="bibr">125</xref>]. All three proteins were slightly downregulated after metformin administration, but upregulated in a hyperinsulinemic environment, with significant changes between both treatments. Therefore, metformin treatment is likely to promote anti-proliferative effects by the regulation of these proteins.</p><table-wrap id="pone.0248103.t007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0248103.t007</object-id><label>Table 7</label><caption><title>Favorable changes in the expression of significantly differential expressed proteins between metformin treatment and hyperinsulinemia.</title></caption><alternatives><graphic id="pone.0248103.t007g" xlink:href="pone.0248103.t007"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" colspan="2" rowspan="1">significantly differential expressed proteins between metformin- and insulin-treated groups</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">favorable metformin effects:</td><td align="left" rowspan="1" colspan="1">AMFR, CCND2, CD63, ERBB3, EZR, GFAP, IRF4, PI3, PLCG2, SORL1, VEGFA, VTCN1, SPP1, TM9SF2</td></tr><tr><td align="left" rowspan="1" colspan="1">favorable insulin effects:</td><td align="left" rowspan="1" colspan="1">CEACAM8, CTSL, F3, GUSB, LGALS1, NT5E, PLAUR, TFRC</td></tr></tbody></table></alternatives></table-wrap><p>In contrast, the following proteins were regulated in a more favorable way during hyperinsulinemia compared to a treatment with metformin: coagulation factor III (F3, tissue factor (TF)), galectin-1 (LGALS1, LEG1), 5&#x02019;-nucleotidase ecto (NT5E, 5NTD), and plasminogen activator urokinase receptor (PLAUR, UPAR). Overexpression of F3, a protein that initiates thrombin formation during hemostasis, effectively enhances angiogenesis as well as coagulation-associated metastasis [<xref rid="pone.0248103.ref126" ref-type="bibr">126</xref>]. LGALS1 covers various biological functions depending on its cellular location, e.g. when expressed intracellularly, LGALS1 contributes to tumor progression via immune suppression, angiogenesis and metastasis [<xref rid="pone.0248103.ref127" ref-type="bibr">127</xref>, <xref rid="pone.0248103.ref128" ref-type="bibr">128</xref>]. NT5E is involved in cellular interaction with ECM proteins such as laminin and fibronectin and NT5E overexpression is known to support tumor proliferation, migration, angiogenesis, and immune escape [<xref rid="pone.0248103.ref129" ref-type="bibr">129</xref>]. The membrane-bound receptor PLAUR activates a cascade of extracellular proteinases with functions in tissue remodeling upon binding of its ligand, urokinase-type plasminogen activator (UPA), and upregulation of PLAUR promotes survival, migration and metastasis of tumor cells <italic>in vitro</italic> [<xref rid="pone.0248103.ref130" ref-type="bibr">130</xref>]. In the present study, the expression of all four discussed proteins was increased after metformin administration and decreased during hyperinsulinemia compared to untreated controls, with significant changes between both treatments. In these cases, metformin treatment is likely to suppress anti-proliferative effects and to favor tumor progression by the regulation of these proteins.</p></sec><sec sec-type="conclusions" id="sec009"><title>5. Conclusion</title><p>The proteomic analysis of changes in the expression of 1,300 different proteins in the human EC cell line HEC-1A revealed that both metformin treatment and insulin supplementation led to anti-tumor as well as some tumor-promoting effects. A set of 80 proteins were selected for a more detailed analysis based on most prominent changes. Metformin and insulin targeted similar pathways and mostly acted on proteins related to proliferation, migration, and changes in the tumor microenvironment, especially cellular immune response. The presented data helps identify proteins affected by metformin treatment as well as insulin supplementation in EC and allows for a better understanding of the mechanism of action of the anti-cancer properties of the biguanide drug, that are still not fully understood. However, further investigations are necessary for selected proteins to confirm the observations and conclusions drawn from the presented data after metformin administration, especially for proteins that were regulated in a favorable way, i.e. AKT3, CCND2, CD63, CD81, GFAP, IL5, IL17A, IRF4, PI3, and VTCN1. In the context of a hyperinsulinemic environment, as seen in obese women or PCOS patients, further proteins might be of interest, i.e. AMFR, CCND2, CD63, ERBB3, EZR, GFAP, IRF4, PI3, PLCG2, SORL1, VEGFA, VTCN1, SPP1, and TM9SF2, because sensitization to insulin due to metformin administration might be able to counteract unfavorable effects on their expression profile that have been induced by hyperinsulinemia.</p></sec><sec sec-type="supplementary-material" id="sec010"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0248103.s001"><label>S1 Table</label><caption><title>Expression of selected proteins in EC cells after treatment with metformin or insulin.</title><p>(PDF)</p></caption><media xlink:href="pone.0248103.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0248103.s002"><label>S1 Fig</label><caption><title>Expression of IL2 and COL1A1 in endometrial cancer cells after treatment with metformin or insulin.</title><p>HEC-1A cells were treated with 0.5 mmol/L metformin or 100 ng/mL insulin. (<bold>A</bold>) Expression of IL2 was analyzed with an ELISA kit (HS200; R&#x00026;D Systems, Minneapolis, Minnesota, MN, USA) according to the manufacturer&#x02019;s protocol. (<bold>B</bold>) Expression of COL1A1 was analyzed with western blot analysis (ab138492; Abcam, Cambridge, UK). Data are presented as expression levels relative to the expression in untreated reference cells (log<sub>2</sub>FC).</p><p>(TIF)</p></caption><media xlink:href="pone.0248103.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0248103.s003"><label>S1 Raw images</label><caption><p>(PDF)</p></caption><media xlink:href="pone.0248103.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank Julia Jauckus for technical assistance.</p></ack><ref-list><title>References</title><ref id="pone.0248103.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Morice</surname><given-names>P</given-names></name>, <name><surname>Leary</surname><given-names>A</given-names></name>, <name><surname>Creutzberg</surname><given-names>C</given-names></name>, <name><surname>Abu-Rustum</surname><given-names>N</given-names></name>, <name><surname>Darai</surname><given-names>E</given-names></name>. <article-title>Endometrial cancer</article-title>. <source>Lancet</source>. <year>2016</year>; <volume>387</volume>(<issue>10023</issue>): <fpage>1094</fpage>&#x02013;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)00130-0</pub-id>
<?supplied-pmid 26354523?><pub-id pub-id-type="pmid">26354523</pub-id></mixed-citation></ref><ref id="pone.0248103.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Amant</surname><given-names>F</given-names></name>, <name><surname>Mirza</surname><given-names>MR</given-names></name>, <name><surname>Koskas</surname><given-names>M</given-names></name>, <name><surname>Creutzberg</surname><given-names>CL</given-names></name>. <article-title>Cancer of the corpus uteri</article-title>. <source>Int J Gynecol Obstet</source>. <year>2018</year>; <volume>143</volume>(<issue>Suppl 2</issue>): <fpage>37</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1002/ijgo.12612</pub-id>
<?supplied-pmid 30306580?><pub-id pub-id-type="pmid">30306580</pub-id></mixed-citation></ref><ref id="pone.0248103.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Garg</surname><given-names>K</given-names></name>, <name><surname>Soslow</surname><given-names>RA</given-names></name>. <article-title>Endometrial carcinoma in women aged 40 years and younger</article-title>. <source>Archives of Pathology &#x00026; Laboratory Medicine</source>. <year>2014</year>; <volume>138</volume>(<issue>3</issue>): <fpage>335</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.5858/arpa.2012-0654-RA</pub-id>
<?supplied-pmid 24576029?><pub-id pub-id-type="pmid">24576029</pub-id></mixed-citation></ref><ref id="pone.0248103.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Byrne</surname><given-names>FL</given-names></name>, <name><surname>Poon</surname><given-names>IK</given-names></name>, <name><surname>Modesitt</surname><given-names>SC</given-names></name>, <name><surname>Tomsig</surname><given-names>JL</given-names></name>, <name><surname>Chow</surname><given-names>JD</given-names></name>, <name><surname>Healy</surname><given-names>ME</given-names></name>, <etal>et al</etal>. <article-title>Metabolic vulnerabilities in endometrial cancer</article-title>. <source>Cancer Res</source>. <year>2014</year>; <volume>74</volume>(<issue>20</issue>): <fpage>5832</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0254</pub-id>
<?supplied-pmid 25205105?><pub-id pub-id-type="pmid">25205105</pub-id></mixed-citation></ref><ref id="pone.0248103.ref005"><label>5</label><mixed-citation publication-type="other">American Cancer Society. Key statistics for endometrial cancer 2020 [accessed 2020 Aug 18]; available from: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html#references">https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html#references</ext-link>.</mixed-citation></ref><ref id="pone.0248103.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Collins</surname><given-names>G</given-names></name>, <name><surname>Mesiano</surname><given-names>S</given-names></name>, <name><surname>DiFeo</surname><given-names>A</given-names></name>. <article-title>Effects of metformin on cellular proliferation and steroid hormone receptors in patient-derived, low-grade endometrial cancer cell lines</article-title>. <source>Reprod Sci</source>. <year>2019</year>; <volume>26</volume>(<issue>5</issue>): <fpage>609</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1177/1933719118779734</pub-id>
<?supplied-pmid 29848180?><pub-id pub-id-type="pmid">29848180</pub-id></mixed-citation></ref><ref id="pone.0248103.ref007"><label>7</label><mixed-citation publication-type="book"><collab>American Cancer Society</collab>. <source>Endometrial cancer causes, risk factors, and prevention</source>: <publisher-name>American Cancer Society</publisher-name>; <year>2019</year> [accessed 2020 Aug 18]; available from: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.org/cancer/endometrial-cancer/causes-risks-prevention.html">https://www.cancer.org/cancer/endometrial-cancer/causes-risks-prevention.html</ext-link>.</mixed-citation></ref><ref id="pone.0248103.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Szablewski</surname><given-names>L.</given-names></name>
<article-title>Diabetes mellitus: influences on cancer risk</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2014</year>; <volume>30</volume>(<issue>7</issue>): <fpage>543</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1002/dmrr.2573</pub-id>
<?supplied-pmid 25044584?><pub-id pub-id-type="pmid">25044584</pub-id></mixed-citation></ref><ref id="pone.0248103.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Shao</surname><given-names>R</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Feng</surname><given-names>Y</given-names></name>, <name><surname>Lin</surname><given-names>JF</given-names></name>, <name><surname>Billig</surname><given-names>H</given-names></name>. <article-title>Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2014</year>; <volume>33</volume>(<issue>1</issue>): <fpage>41</fpage>. <pub-id pub-id-type="doi">10.1186/1756-9966-33-41</pub-id>
<?supplied-pmid 24887156?><pub-id pub-id-type="pmid">24887156</pub-id></mixed-citation></ref><ref id="pone.0248103.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>O&#x02019;Connor</surname><given-names>KA</given-names></name>, <name><surname>Ferrell</surname><given-names>RJ</given-names></name>, <name><surname>Brindle</surname><given-names>E</given-names></name>, <name><surname>Shofer</surname><given-names>J</given-names></name>, <name><surname>Holman</surname><given-names>DJ</given-names></name>, <name><surname>Miller</surname><given-names>RC</given-names></name>, <etal>et al</etal>. <article-title>Total and unopposed estrogen exposure across stages of the transition to menopause</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2009</year>; <volume>18</volume>(<issue>3</issue>): <fpage>828</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-08-0996</pub-id>
<?supplied-pmid 19240232?><pub-id pub-id-type="pmid">19240232</pub-id></mixed-citation></ref><ref id="pone.0248103.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Clarke</surname><given-names>CL</given-names></name>, <name><surname>Sutherland</surname><given-names>RL</given-names></name>. <article-title>Progestin regulation of cellular proliferation</article-title>. <source>Endocr Rev</source>. <year>1990</year>; <volume>11</volume>(<issue>2</issue>): <fpage>266</fpage>&#x02013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1210/edrv-11-2-266</pub-id>
<?supplied-pmid 2114281?><pub-id pub-id-type="pmid">2114281</pub-id></mixed-citation></ref><ref id="pone.0248103.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Modesitt</surname><given-names>SC</given-names></name>, <name><surname>Geffel</surname><given-names>DL</given-names></name>, <name><surname>Via</surname><given-names>J</given-names></name>, <name><surname>A</surname><given-names>LW</given-names></name>. <article-title>Morbidly obese women with and without endometrial cancer: are there differences in measured physical fitness, body composition, or hormones</article-title>? <source>Gynecol Oncol</source>. <year>2012</year>; <volume>124</volume>(<issue>3</issue>): <fpage>431</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2011.11.013</pub-id>
<?supplied-pmid 22101155?><pub-id pub-id-type="pmid">22101155</pub-id></mixed-citation></ref><ref id="pone.0248103.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Joung</surname><given-names>KH</given-names></name>, <name><surname>Jeong</surname><given-names>JW</given-names></name>, <name><surname>Ku</surname><given-names>BJ</given-names></name>. <article-title>The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms</article-title>. <source>Biomed Res Int</source>. <year>2015</year>; <volume>2015</volume>: <fpage>920618</fpage>. <pub-id pub-id-type="doi">10.1155/2015/920618</pub-id>
<?supplied-pmid 25866823?><pub-id pub-id-type="pmid">25866823</pub-id></mixed-citation></ref><ref id="pone.0248103.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Flory</surname><given-names>J</given-names></name>, <name><surname>Lipska</surname><given-names>K</given-names></name>. <article-title>Metformin in 2019</article-title>. <source>JAMA</source>. <year>2019</year>; <volume>321</volume>(<issue>19</issue>): <fpage>1926</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2019.3805</pub-id>
<?supplied-pmid 31009043?><pub-id pub-id-type="pmid">31009043</pub-id></mixed-citation></ref><ref id="pone.0248103.ref015"><label>15</label><mixed-citation publication-type="book"><name><surname>Dewan</surname><given-names>S</given-names></name>, <name><surname>Wilding</surname><given-names>J</given-names></name>. <chapter-title>Adult obesity: metabolic syndrome, diabetes and non&#x02010;alcoholic steatohepatitis</chapter-title> In: <name><surname>Kopelman</surname><given-names>PG</given-names></name>, <name><surname>Caterson</surname><given-names>ID</given-names></name>, <name><surname>Dietz</surname><given-names>WH</given-names></name>, editors. <source>Clinical Obesity in Adults and Children</source>
<edition designator="2">2nd ed</edition>. <publisher-loc>Malden (MA)</publisher-loc>: <publisher-name>Blackwell Publishing</publisher-name>; <year>2005</year>. p. <fpage>249</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1002/9780470987087</pub-id></mixed-citation></ref><ref id="pone.0248103.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Meireles</surname><given-names>CG</given-names></name>, <name><surname>Pereira</surname><given-names>SA</given-names></name>, <name><surname>Valadares</surname><given-names>LP</given-names></name>, <name><surname>R&#x000ea;go</surname><given-names>DF</given-names></name>, <name><surname>Simeoni</surname><given-names>LA</given-names></name>, <name><surname>Guerra</surname><given-names>ENS</given-names></name>, <etal>et al</etal>. <article-title>Effects of metformin on endometrial cancer: systematic review and meta-analysis</article-title>. <source>Gynecol Oncol</source>. <year>2017</year>; <volume>147</volume>(<issue>1</issue>): <fpage>167</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2017.07.120</pub-id>
<?supplied-pmid 28760367?><pub-id pub-id-type="pmid">28760367</pub-id></mixed-citation></ref><ref id="pone.0248103.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Libby</surname><given-names>G</given-names></name>, <name><surname>Donnelly</surname><given-names>LA</given-names></name>, <name><surname>Donnan</surname><given-names>PT</given-names></name>, <name><surname>Alessi</surname><given-names>DR</given-names></name>, <name><surname>Morris</surname><given-names>AD</given-names></name>, <name><surname>Evans</surname><given-names>JM</given-names></name>. <article-title>New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2009</year>; <volume>32</volume>(<issue>9</issue>): <fpage>1620</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.2337/dc08-2175</pub-id>
<?supplied-pmid 19564453?><pub-id pub-id-type="pmid">19564453</pub-id></mixed-citation></ref><ref id="pone.0248103.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Evans</surname><given-names>JMM</given-names></name>, <name><surname>Donnelly</surname><given-names>LA</given-names></name>, <name><surname>Emslie-Smith</surname><given-names>AM</given-names></name>, <name><surname>Alessi</surname><given-names>DR</given-names></name>, <name><surname>Morris</surname><given-names>AD</given-names></name>. <article-title>Metformin and reduced risk of cancer in diabetic patients</article-title>. <source>British Medical Journal</source>. <year>2005</year>; <volume>330</volume>(<issue>7503</issue>): <fpage>1304</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.38415.708634.F7</pub-id>
<?supplied-pmid 15849206?><pub-id pub-id-type="pmid">15849206</pub-id></mixed-citation></ref><ref id="pone.0248103.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Ko</surname><given-names>EM</given-names></name>, <name><surname>Walter</surname><given-names>P</given-names></name>, <name><surname>Jackson</surname><given-names>A</given-names></name>, <name><surname>Clark</surname><given-names>L</given-names></name>, <name><surname>Franasiak</surname><given-names>J</given-names></name>, <name><surname>Bolac</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Metformin is associated with improved survival in endometrial cancer</article-title>. <source>Gynecol Oncol</source>. <year>2014</year>; <volume>132</volume>(<issue>2</issue>): <fpage>438</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2013.11.021</pub-id>
<?supplied-pmid 24269517?><pub-id pub-id-type="pmid">24269517</pub-id></mixed-citation></ref><ref id="pone.0248103.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Nevadunsky</surname><given-names>NS</given-names></name>, <name><surname>Van Arsdale</surname><given-names>A</given-names></name>, <name><surname>Strickler</surname><given-names>HD</given-names></name>, <name><surname>Moadel</surname><given-names>A</given-names></name>, <name><surname>Kaur</surname><given-names>G</given-names></name>, <name><surname>Frimer</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Metformin use and endometrial cancer survival</article-title>. <source>Gynecol Oncol</source>. <year>2014</year>; <volume>132</volume>(<issue>1</issue>): <fpage>236</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2013.10.026</pub-id>
<?supplied-pmid 24189334?><pub-id pub-id-type="pmid">24189334</pub-id></mixed-citation></ref><ref id="pone.0248103.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Currie</surname><given-names>CJ</given-names></name>, <name><surname>Poole</surname><given-names>CD</given-names></name>, <name><surname>Jenkins-Jones</surname><given-names>S</given-names></name>, <name><surname>Gale</surname><given-names>EA</given-names></name>, <name><surname>Johnson</surname><given-names>JA</given-names></name>, <name><surname>Morgan</surname><given-names>CL</given-names></name>. <article-title>Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival</article-title>. <source>Diabetes Care</source>. <year>2012</year>; <volume>35</volume>(<issue>2</issue>): <fpage>299</fpage>&#x02013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.2337/dc11-1313</pub-id>
<?supplied-pmid 22266734?><pub-id pub-id-type="pmid">22266734</pub-id></mixed-citation></ref><ref id="pone.0248103.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Pollak</surname><given-names>MN</given-names></name>. <article-title>Investigating metformin for cancer prevention and treatment: the end of the beginning</article-title>. <source>Cancer Discov</source>. <year>2012</year>; <volume>2</volume>(<issue>9</issue>): <fpage>778</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0263</pub-id>
<?supplied-pmid 22926251?><pub-id pub-id-type="pmid">22926251</pub-id></mixed-citation></ref><ref id="pone.0248103.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Karnevi</surname><given-names>E</given-names></name>, <name><surname>Said</surname><given-names>K</given-names></name>, <name><surname>Andersson</surname><given-names>R</given-names></name>, <name><surname>Rosendahl</surname><given-names>AH</given-names></name>. <article-title>Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells</article-title>. <source>BMC Cancer</source>. <year>2013</year>; <volume>13</volume>(<issue>1</issue>): <fpage>235</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-13-235</pub-id>
<?supplied-pmid 23663483?><pub-id pub-id-type="pmid">23663483</pub-id></mixed-citation></ref><ref id="pone.0248103.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>JL</given-names></name>, <name><surname>Ji</surname><given-names>M</given-names></name>, <name><surname>Yuan</surname><given-names>ZF</given-names></name>, <name><surname>Peng</surname><given-names>Z</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells</article-title>. <source>Oncol Lett</source>. <year>2014</year>; <volume>8</volume>(<issue>5</issue>): <fpage>1993</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2014.2466</pub-id>
<?supplied-pmid 25289085?><pub-id pub-id-type="pmid">25289085</pub-id></mixed-citation></ref><ref id="pone.0248103.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Pierotti</surname><given-names>MA</given-names></name>, <name><surname>Berrino</surname><given-names>F</given-names></name>, <name><surname>Gariboldi</surname><given-names>M</given-names></name>, <name><surname>Melani</surname><given-names>C</given-names></name>, <name><surname>Mogavero</surname><given-names>A</given-names></name>, <name><surname>Negri</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects</article-title>. <source>Oncogene</source>. <year>2013</year>; <volume>32</volume>(<issue>12</issue>): <fpage>1475</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.181</pub-id>
<?supplied-pmid 22665053?><pub-id pub-id-type="pmid">22665053</pub-id></mixed-citation></ref><ref id="pone.0248103.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>H</given-names></name>, <name><surname>Kong</surname><given-names>W</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Han</surname><given-names>J</given-names></name>, <name><surname>Clark</surname><given-names>LH</given-names></name>, <name><surname>Yin</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Reversal of obesity-driven aggressiveness of endometrial cancer by metformin</article-title>. <source>Am J Cancer Res</source>. <year>2019</year>; <volume>9</volume>(<issue>10</issue>): <fpage>2170</fpage>&#x02013;<lpage>93</lpage>. <?supplied-pmid 31720081?><pub-id pub-id-type="pmid">31720081</pub-id></mixed-citation></ref><ref id="pone.0248103.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Daugan</surname><given-names>M</given-names></name>, <name><surname>Dufa&#x000ff; Wojcicki</surname><given-names>A</given-names></name>, <name><surname>d&#x02019;Hayer</surname><given-names>B</given-names></name>, <name><surname>Boudy</surname><given-names>V</given-names></name>. <article-title>Metformin: an anti-diabetic drug to fight cancer</article-title>. <source>Pharmacol Res</source>. <year>2016</year>; <volume>113</volume>(<issue>Pt. A</issue>): <fpage>675</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2016.10.006</pub-id>
<?supplied-pmid 27720766?><pub-id pub-id-type="pmid">27720766</pub-id></mixed-citation></ref><ref id="pone.0248103.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Kandoth</surname><given-names>C</given-names></name>, <name><surname>Schultz</surname><given-names>N</given-names></name>, <name><surname>Cherniack</surname><given-names>AD</given-names></name>, <name><surname>Akbani</surname><given-names>R</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Shen</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Integrated genomic characterization of endometrial carcinoma</article-title>. <source>Nature</source>. <year>2013</year>; <volume>497</volume>(<issue>7447</issue>): <fpage>67</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/nature12113</pub-id>
<?supplied-pmid 23636398?><pub-id pub-id-type="pmid">23636398</pub-id></mixed-citation></ref><ref id="pone.0248103.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Weigelt</surname><given-names>B</given-names></name>, <name><surname>Banerjee</surname><given-names>S</given-names></name>. <article-title>Molecular targets and targeted therapeutics in endometrial cancer</article-title>. <source>Curr Opin Oncol</source>. <year>2012</year>; <volume>24</volume>(<issue>5</issue>): <fpage>554</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1097/CCO.0b013e328354e585</pub-id>
<?supplied-pmid 22581357?><pub-id pub-id-type="pmid">22581357</pub-id></mixed-citation></ref><ref id="pone.0248103.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Cheung</surname><given-names>LW</given-names></name>, <name><surname>Hennessy</surname><given-names>BT</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Yu</surname><given-names>S</given-names></name>, <name><surname>Myers</surname><given-names>AP</given-names></name>, <name><surname>Djordjevic</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability</article-title>. <source>Cancer Discov</source>. <year>2011</year>; <volume>1</volume>(<issue>2</issue>): <fpage>170</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-11-0039</pub-id>
<?supplied-pmid 21984976?><pub-id pub-id-type="pmid">21984976</pub-id></mixed-citation></ref><ref id="pone.0248103.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Markowska</surname><given-names>A</given-names></name>, <name><surname>Pawa&#x00142;owska</surname><given-names>M</given-names></name>, <name><surname>Filas</surname><given-names>V</given-names></name>, <name><surname>Korski</surname><given-names>K</given-names></name>, <name><surname>Grybo&#x0015b;</surname><given-names>M</given-names></name>, <name><surname>Sajdak</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Does metformin affect ER, PR, IGF-1R, &#x003b2;-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?</article-title>
<source>Diabetol Metab Syndr</source>. <year>2013</year>; <volume>5</volume>(<issue>1</issue>): <fpage>76</fpage>. <pub-id pub-id-type="doi">10.1186/1758-5996-5-76</pub-id>
<?supplied-pmid 24308813?><pub-id pub-id-type="pmid">24308813</pub-id></mixed-citation></ref><ref id="pone.0248103.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Kalender</surname><given-names>A</given-names></name>, <name><surname>Selvaraj</surname><given-names>A</given-names></name>, <name><surname>Kim</surname><given-names>SY</given-names></name>, <name><surname>Gulati</surname><given-names>P</given-names></name>, <name><surname>Br&#x000fb;l&#x000e9;</surname><given-names>S</given-names></name>, <name><surname>Viollet</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner</article-title>. <source>Cell Metab</source>. <year>2010</year>; <volume>11</volume>(<issue>5</issue>): <fpage>390</fpage>&#x02013;<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2010.03.014</pub-id>
<?supplied-pmid 20444419?><pub-id pub-id-type="pmid">20444419</pub-id></mixed-citation></ref><ref id="pone.0248103.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Kourelis</surname><given-names>TV</given-names></name>, <name><surname>Siegel</surname><given-names>RD</given-names></name>. <article-title>Metformin and cancer: new applications for an old drug</article-title>. <source>Med Oncol</source>. <year>2012</year>; <volume>29</volume>(<issue>2</issue>): <fpage>1314</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s12032-011-9846-7</pub-id>
<?supplied-pmid 21301998?><pub-id pub-id-type="pmid">21301998</pub-id></mixed-citation></ref><ref id="pone.0248103.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>J</given-names></name>, <name><surname>Yesilkanal</surname><given-names>AE</given-names></name>, <name><surname>Wynne</surname><given-names>JP</given-names></name>, <name><surname>Frankenberger</surname><given-names>C</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Yan</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism</article-title>. <source>Nature</source>. <year>2019</year>; <volume>568</volume>(<issue>7751</issue>): <fpage>254</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1005-x</pub-id>
<?supplied-pmid 30842661?><pub-id pub-id-type="pmid">30842661</pub-id></mixed-citation></ref><ref id="pone.0248103.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Vial</surname><given-names>G</given-names></name>, <name><surname>Detaille</surname><given-names>D</given-names></name>, <name><surname>Guigas</surname><given-names>B</given-names></name>. <article-title>Role of mitochondria in the mechanism(s) of action of metformin</article-title>. <source>Front Endocrinol (Lausanne).</source>
<year>2019</year>; <volume>10</volume>: <fpage>294</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2019.00294</pub-id>
<?supplied-pmid 31133988?><pub-id pub-id-type="pmid">31133988</pub-id></mixed-citation></ref><ref id="pone.0248103.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Saini</surname><given-names>N</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>. <article-title>Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells</article-title>. <source>Acta Biochim Biophysica Sin (Shanghai)</source>. <year>2018</year>; <volume>50</volume>(<issue>2</issue>): <fpage>133</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1093/abbs/gmx106</pub-id>
<?supplied-pmid 29342230?><pub-id pub-id-type="pmid">29342230</pub-id></mixed-citation></ref><ref id="pone.0248103.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Deng</surname><given-names>XS</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Deng</surname><given-names>A</given-names></name>, <name><surname>Liu</surname><given-names>B</given-names></name>, <name><surname>Edgerton</surname><given-names>SM</given-names></name>, <name><surname>Lind</surname><given-names>SE</given-names></name>, <etal>et al</etal>. <article-title>Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers</article-title>. <source>Cell Cycle</source>. <year>2012</year>; <volume>11</volume>(<issue>2</issue>): <fpage>367</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.4161/cc.11.2.18813</pub-id>
<?supplied-pmid 22189713?><pub-id pub-id-type="pmid">22189713</pub-id></mixed-citation></ref><ref id="pone.0248103.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Aljofan</surname><given-names>M</given-names></name>, <name><surname>Riethmacher</surname><given-names>D</given-names></name>. <article-title>Anticancer activity of metformin: a systematic review of the literature</article-title>. <source>Future Sci OA</source>. <year>2019</year>; <volume>5</volume>(<issue>8</issue>): <fpage>FSO410</fpage>. <pub-id pub-id-type="doi">10.2144/fsoa-2019-0053</pub-id>
<?supplied-pmid 31534778?><pub-id pub-id-type="pmid">31534778</pub-id></mixed-citation></ref><ref id="pone.0248103.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Tseng</surname><given-names>HW</given-names></name>, <name><surname>Li</surname><given-names>SC</given-names></name>, <name><surname>Tsai</surname><given-names>KW</given-names></name>. <article-title>Metformin treatment suppresses melanoma cell growth and motility through modulation of microRNA expression</article-title>. <source>Cancers</source>. <year>2019</year>; <volume>11</volume>(<issue>2</issue>): <fpage>209</fpage>. <pub-id pub-id-type="doi">10.3390/cancers11020209</pub-id>
<?supplied-pmid 30754729?><pub-id pub-id-type="pmid">30754729</pub-id></mixed-citation></ref><ref id="pone.0248103.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Kuramoto</surname><given-names>H</given-names></name>, <name><surname>Tamura</surname><given-names>S</given-names></name>, <name><surname>Notake</surname><given-names>Y</given-names></name>. <article-title>Establishment of a cell line of human endometrial adenocarcinoma in vitro</article-title>. <source>Am J Obstet Gynecol</source>. <year>1972</year>; <volume>114</volume>(<issue>8</issue>): <fpage>1012</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/0002-9378(72)90861-7</pub-id>
<?supplied-pmid 4673779?><pub-id pub-id-type="pmid">4673779</pub-id></mixed-citation></ref><ref id="pone.0248103.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Kuramoto</surname><given-names>H</given-names></name>, <name><surname>Hamano</surname><given-names>M</given-names></name>, <name><surname>Imai</surname><given-names>M</given-names></name>. <article-title>HEC-1 cells</article-title>. <source>Hum Cell</source>. <year>2002</year>; <volume>15</volume>(<issue>2</issue>): <fpage>81</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-0774.2002.tb00103.x</pub-id>
<?supplied-pmid 12227503?><pub-id pub-id-type="pmid">12227503</pub-id></mixed-citation></ref><ref id="pone.0248103.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Hevir-Kene</surname><given-names>N</given-names></name>, <name><surname>Ri&#x0017e;ner</surname><given-names>TL</given-names></name>. <article-title>The endometrial cancer cell lines Ishikawa and HEC-1A, and the control cell line HIEEC, differ in expression of estrogen biosynthetic and metabolic genes, and in androstenedione and estrone-sulfate metabolism</article-title>. <source>Chem Biol Interact</source>. <year>2015</year>; <volume>234</volume>: <fpage>309</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2014.11.015</pub-id>
<?supplied-pmid 25437045?><pub-id pub-id-type="pmid">25437045</pub-id></mixed-citation></ref><ref id="pone.0248103.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Czech</surname><given-names>MP</given-names></name>. <article-title>Insulin action and resistance in obesity and type 2 diabetes</article-title>. <source>Nat Med</source>. <year>2017</year>; <volume>23</volume>(<issue>7</issue>): <fpage>804</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4350</pub-id>
<?supplied-pmid 28697184?><pub-id pub-id-type="pmid">28697184</pub-id></mixed-citation></ref><ref id="pone.0248103.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Filigheddu</surname><given-names>N</given-names></name>, <name><surname>Sampietro</surname><given-names>S</given-names></name>, <name><surname>Chianale</surname><given-names>F</given-names></name>, <name><surname>Porporato</surname><given-names>PE</given-names></name>, <name><surname>Gaggianesi</surname><given-names>M</given-names></name>, <name><surname>Gregnanin</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Diacylglycerol kinase &#x003b1; mediates 17-&#x003b2;-estradiol-induced proliferation, motility, and anchorage-independent growth of Hec-1A endometrial cancer cell line through the G protein-coupled estrogen receptor GPR30</article-title>. <source>Cell Signal</source>. <year>2011</year>; <volume>23</volume>(<issue>12</issue>): <fpage>1988</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2011.07.009</pub-id>
<?supplied-pmid 21802511?><pub-id pub-id-type="pmid">21802511</pub-id></mixed-citation></ref><ref id="pone.0248103.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Ritchie</surname><given-names>ME</given-names></name>, <name><surname>Phipson</surname><given-names>B</given-names></name>, <name><surname>Wu</surname><given-names>D</given-names></name>, <name><surname>Hu</surname><given-names>Y</given-names></name>, <name><surname>Law</surname><given-names>CW</given-names></name>, <name><surname>Shi</surname><given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year>; <volume>43</volume>(<issue>7</issue>): <fpage>e47</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>
<?supplied-pmid 25605792?><pub-id pub-id-type="pmid">25605792</pub-id></mixed-citation></ref><ref id="pone.0248103.ref046"><label>46</label><mixed-citation publication-type="book"><collab>R Core Team</collab>. <source>R: a language and environment for statistical computing</source>. <publisher-loc>Vienna</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="pone.0248103.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Sill</surname><given-names>M</given-names></name>, <name><surname>Schr&#x000f6;der</surname><given-names>C</given-names></name>, <name><surname>Hoheisel</surname><given-names>JD</given-names></name>, <name><surname>Benner</surname><given-names>A</given-names></name>, <name><surname>Zucknick</surname><given-names>M</given-names></name>. <article-title>Assessment and optimisation of normalisation methods for dual-colour antibody microarrays</article-title>. <source>BMC Bioinformatics</source>. <year>2010</year>; <volume>11</volume>: <fpage>556</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-11-556</pub-id>
<?supplied-pmid 21073702?><pub-id pub-id-type="pmid">21073702</pub-id></mixed-citation></ref><ref id="pone.0248103.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Hochberg</surname><given-names>Y</given-names></name>, <name><surname>Benjamini</surname><given-names>Y</given-names></name>. <article-title>More powerful procedures for multiple significance testing</article-title>. <source>Stat Med</source>. <year>1990</year>; <volume>9</volume>(<issue>7</issue>): <fpage>811</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/sim.4780090710</pub-id>
<?supplied-pmid 2218183?><pub-id pub-id-type="pmid">2218183</pub-id></mixed-citation></ref><ref id="pone.0248103.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Hulsen</surname><given-names>T</given-names></name>, <name><surname>de Vlieg</surname><given-names>J</given-names></name>, <name><surname>Alkema</surname><given-names>W</given-names></name>. <article-title>BioVenn&#x02014;A web application for the comparison and visualization of biological lists using area-proportional Venn diagrams</article-title>. <source>BMC Genomics</source>. <year>2008</year>; <volume>9</volume>(<issue>1</issue>): <fpage>488</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2164-9-488</pub-id>
<?supplied-pmid 18925949?><pub-id pub-id-type="pmid">18925949</pub-id></mixed-citation></ref><ref id="pone.0248103.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Szklarczyk</surname><given-names>D</given-names></name>, <name><surname>Gable</surname><given-names>AL</given-names></name>, <name><surname>Lyon</surname><given-names>D</given-names></name>, <name><surname>Junge</surname><given-names>A</given-names></name>, <name><surname>Wyder</surname><given-names>S</given-names></name>, <name><surname>Huerta-Cepas</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title>. <source>Nucleic Acids Res</source>. <year>2019</year>; <volume>47</volume>(<issue>D1</issue>): <fpage>D607</fpage>&#x02013;<lpage>D13</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id>
<?supplied-pmid 30476243?><pub-id pub-id-type="pmid">30476243</pub-id></mixed-citation></ref><ref id="pone.0248103.ref051"><label>51</label><mixed-citation publication-type="journal"><collab>The Gene Ontology Consortium</collab>. <article-title>The gene ontology resource: 20 years and still GOing strong</article-title>. <source>Nucleic Acids Res</source>. <year>2018</year>; <volume>47</volume>(<issue>D1</issue>): <fpage>D330</fpage>&#x02013;<lpage>D8</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1055</pub-id>
<?supplied-pmid 30395331?><pub-id pub-id-type="pmid">30395331</pub-id></mixed-citation></ref><ref id="pone.0248103.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Ashburner</surname><given-names>M</given-names></name>, <name><surname>Ball</surname><given-names>CA</given-names></name>, <name><surname>Blake</surname><given-names>JA</given-names></name>, <name><surname>Botstein</surname><given-names>D</given-names></name>, <name><surname>Butler</surname><given-names>H</given-names></name>, <name><surname>Cherry</surname><given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>Gene ontology: tool for the unification of biology</article-title>. <source>Nat Genet</source>. <year>2000</year>; <volume>25</volume>(<issue>1</issue>): <fpage>25</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/75556</pub-id>
<?supplied-pmid 10802651?><pub-id pub-id-type="pmid">10802651</pub-id></mixed-citation></ref><ref id="pone.0248103.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Dennis</surname><given-names>G</given-names></name>, <name><surname>Sherman</surname><given-names>BT</given-names></name>, <name><surname>Hosack</surname><given-names>DA</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Gao</surname><given-names>W</given-names></name>, <name><surname>Lane</surname><given-names>HC</given-names></name>, <etal>et al</etal>. <article-title>DAVID: Database for annotation, visualization, and integrated discovery</article-title>. <source>Genome Biol</source>. <year>2003</year>; <volume>4</volume>(<issue>9</issue>): <fpage>R60</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2003-4-9-r60</pub-id></mixed-citation></ref><ref id="pone.0248103.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>DW</given-names></name>, <name><surname>Sherman</surname><given-names>BT</given-names></name>, <name><surname>Lempicki</surname><given-names>RA</given-names></name>. <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source>Nat Protoc</source>. <year>2009</year>; <volume>4</volume>(<issue>1</issue>): <fpage>44</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id>
<?supplied-pmid 19131956?><pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation></ref><ref id="pone.0248103.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>DW</given-names></name>, <name><surname>Sherman</surname><given-names>BT</given-names></name>, <name><surname>Lempicki</surname><given-names>RA</given-names></name>. <article-title>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</article-title>. <source>Nucleic Acids Res</source>. <year>2009</year>; <volume>37</volume>(<issue>1</issue>): <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn923</pub-id>
<?supplied-pmid 19033363?><pub-id pub-id-type="pmid">19033363</pub-id></mixed-citation></ref><ref id="pone.0248103.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Kanehisa</surname><given-names>M</given-names></name>, <name><surname>Goto</surname><given-names>S</given-names></name>. <article-title>KEGG: Kyoto encyclopedia of genes and genomes</article-title>. <source>Nucleic Acids Res</source>. <year>2000</year>; <volume>28</volume>(<issue>1</issue>): <fpage>27</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id>
<?supplied-pmid 10592173?><pub-id pub-id-type="pmid">10592173</pub-id></mixed-citation></ref><ref id="pone.0248103.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Flory</surname><given-names>J</given-names></name>, <name><surname>Lipska</surname><given-names>K</given-names></name>. <article-title>Metformin in 2019</article-title>. <source>JAMA</source>. <year>2019</year>; <volume>321</volume>(<issue>19</issue>): <fpage>1926</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2019.3805</pub-id>
<?supplied-pmid 31009043?><pub-id pub-id-type="pmid">31009043</pub-id></mixed-citation></ref><ref id="pone.0248103.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Mallik</surname><given-names>R</given-names></name>, <name><surname>Chowdhury</surname><given-names>TA</given-names></name>. <article-title>Metformin in cancer</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2018</year>; <volume>143</volume>: <fpage>409</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2018.05.023</pub-id>
<?supplied-pmid 29807101?><pub-id pub-id-type="pmid">29807101</pub-id></mixed-citation></ref><ref id="pone.0248103.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Qiang</surname><given-names>P</given-names></name>, <name><surname>Shao</surname><given-names>Y</given-names></name>, <name><surname>Sun</surname><given-names>YP</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>LJ</given-names></name>. <article-title>Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2019</year>; <volume>23</volume>(<issue>4</issue>): <fpage>1778</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_201902_17140</pub-id>
<?supplied-pmid 30840303?><pub-id pub-id-type="pmid">30840303</pub-id></mixed-citation></ref><ref id="pone.0248103.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Schuiveling</surname><given-names>M</given-names></name>, <name><surname>Vazirpanah</surname><given-names>N</given-names></name>, <name><surname>Radstake</surname><given-names>T</given-names></name>, <name><surname>Zimmermann</surname><given-names>M</given-names></name>, <name><surname>Broen</surname><given-names>JCA</given-names></name>. <article-title>Metformin, a new era for an old drug in the treatment of immune mediated disease?</article-title>
<source>Curr Drug Targets</source>. <year>2018</year>; <volume>19</volume>(<issue>8</issue>): <fpage>945</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.2174/1389450118666170613081730</pub-id>
<?supplied-pmid 28606032?><pub-id pub-id-type="pmid">28606032</pub-id></mixed-citation></ref><ref id="pone.0248103.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Marcucci</surname><given-names>F</given-names></name>, <name><surname>Romeo</surname><given-names>E</given-names></name>, <name><surname>Caserta</surname><given-names>CA</given-names></name>, <name><surname>Rumio</surname><given-names>C</given-names></name>, <name><surname>Lefoulon</surname><given-names>F</given-names></name>. <article-title>Context-dependent pharmacological effects of metformin on the immune system</article-title>. <source>Trends Pharmacol Sci</source>. <year>2020</year>; <volume>41</volume>(<issue>3</issue>): <fpage>162</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2020.01.003</pub-id>
<?supplied-pmid 32033771?><pub-id pub-id-type="pmid">32033771</pub-id></mixed-citation></ref><ref id="pone.0248103.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>JC</given-names></name>, <name><surname>An</surname><given-names>R</given-names></name>, <name><surname>Jiang</surname><given-names>YQ</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>. <article-title>Effects and mechanisms of metformin on the proliferation of esophageal cancer cells in vitro and in vivo</article-title>. <source>Cancer Res Treat</source>. <year>2017</year>; <volume>49</volume>(<issue>3</issue>): <fpage>778</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.4143/crt.2015.485</pub-id>
<?supplied-pmid 27857021?><pub-id pub-id-type="pmid">27857021</pub-id></mixed-citation></ref><ref id="pone.0248103.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Jia</surname><given-names>K</given-names></name>, <name><surname>Dong</surname><given-names>Y</given-names></name>, <name><surname>Ma</surname><given-names>W</given-names></name>. <article-title>Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway</article-title>. <source>Exp Ther Med</source>. <year>2015</year>; <volume>9</volume>(<issue>4</issue>): <fpage>1401</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2015.2220</pub-id>
<?supplied-pmid 25780442?><pub-id pub-id-type="pmid">25780442</pub-id></mixed-citation></ref><ref id="pone.0248103.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>X</given-names></name>, <name><surname>Liu</surname><given-names>G</given-names></name>, <name><surname>Guo</surname><given-names>J</given-names></name>, <name><surname>Su</surname><given-names>Z</given-names></name>. <article-title>The PI3K/AKT pathway in obesity and type 2 diabetes</article-title>. <source>Int J Biol Sci</source>. <year>2018</year>; <volume>14</volume>(<issue>11</issue>): <fpage>1483</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.27173</pub-id>
<?supplied-pmid 30263000?><pub-id pub-id-type="pmid">30263000</pub-id></mixed-citation></ref><ref id="pone.0248103.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Gallagher</surname><given-names>EJ</given-names></name>, <name><surname>Fierz</surname><given-names>Y</given-names></name>, <name><surname>Vijayakumar</surname><given-names>A</given-names></name>, <name><surname>Haddad</surname><given-names>N</given-names></name>, <name><surname>Yakar</surname><given-names>S</given-names></name>, <name><surname>LeRoith</surname><given-names>D</given-names></name>. <article-title>Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia</article-title>. <source>Oncogene</source>. <year>2012</year>; <volume>31</volume>(<issue>27</issue>): <fpage>3213</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2011.495</pub-id>
<?supplied-pmid 22037215?><pub-id pub-id-type="pmid">22037215</pub-id></mixed-citation></ref><ref id="pone.0248103.ref066"><label>66</label><mixed-citation publication-type="book"><name><surname>&#x0015a;widerska</surname><given-names>E</given-names></name>, <name><surname>Strycharz</surname><given-names>J</given-names></name>, <name><surname>Wr&#x000f3;blewski</surname><given-names>A</given-names></name>, <name><surname>Szemraj</surname><given-names>J</given-names></name>, <name><surname>Drzewoski</surname><given-names>J</given-names></name>, <name><surname>&#x0015a;liwi&#x00144;ska</surname><given-names>A</given-names></name>. <chapter-title>Role of PI3K/AKT pathway in insulin-mediated glucose uptake</chapter-title>. In: <name><surname>Szablewski</surname><given-names>L</given-names></name>, editor. <source>Blood Glucose Levels</source>. Vol. <volume>1</volume>, <edition designator="1">1st ed</edition>. <publisher-loc>London</publisher-loc>: <publisher-name>IntechOpen</publisher-name>; <year>2020</year>. p. <fpage>1</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.5772/intechopen.80402</pub-id></mixed-citation></ref><ref id="pone.0248103.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>SC</given-names></name>, <name><surname>Bassi</surname><given-names>DE</given-names></name>, <name><surname>Zhang</surname><given-names>SY</given-names></name>, <name><surname>Holoran</surname><given-names>D</given-names></name>, <name><surname>Conti</surname><given-names>CJ</given-names></name>, <name><surname>Klein-Szanto</surname><given-names>AJ</given-names></name>. <article-title>Overexpression of cyclin D2 is associated with increased in vivo invasiveness of human squamous carcinoma cells</article-title>. <source>Mol Carcinog</source>. <year>2002</year>; <volume>34</volume>(<issue>3</issue>): <fpage>131</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/mc.10057</pub-id>
<?supplied-pmid 12112307?><pub-id pub-id-type="pmid">12112307</pub-id></mixed-citation></ref><ref id="pone.0248103.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Koyama-Nasu</surname><given-names>R</given-names></name>, <name><surname>Nasu-Nishimura</surname><given-names>Y</given-names></name>, <name><surname>Todo</surname><given-names>T</given-names></name>, <name><surname>Ino</surname><given-names>Y</given-names></name>, <name><surname>Saito</surname><given-names>N</given-names></name>, <name><surname>Aburatani</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells</article-title>. <source>Oncogene</source>. <year>2013</year>; <volume>32</volume>(<issue>33</issue>): <fpage>3840</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.399</pub-id>
<?supplied-pmid 22964630?><pub-id pub-id-type="pmid">22964630</pub-id></mixed-citation></ref><ref id="pone.0248103.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Vences-Catalan</surname><given-names>F</given-names></name>, <name><surname>Duault</surname><given-names>C</given-names></name>, <name><surname>Kuo</surname><given-names>CC</given-names></name>, <name><surname>Rajapaksa</surname><given-names>R</given-names></name>, <name><surname>Levy</surname><given-names>R</given-names></name>, <name><surname>Levy</surname><given-names>S</given-names></name>. <article-title>CD81 as a tumor target</article-title>. <source>Biochem Soc Trans</source>. <year>2017</year>; <volume>45</volume>(<issue>2</issue>): <fpage>531</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1042/BST20160478</pub-id>
<?supplied-pmid 28408492?><pub-id pub-id-type="pmid">28408492</pub-id></mixed-citation></ref><ref id="pone.0248103.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>N</given-names></name>, <name><surname>Zuo</surname><given-names>L</given-names></name>, <name><surname>Zheng</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>G</given-names></name>, <name><surname>Hu</surname><given-names>X</given-names></name>. <article-title>Increased expression of CD81 in breast cancer tissue is associated with reduced patient prognosis and increased cell migration and proliferation in MDA-MB-231 and MDA-MB-435S human breast cancer cell lines in vitro</article-title>. <source>Med Sci Monit</source>. <year>2018</year>; <volume>24</volume>: <fpage>5739</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.12659/MSM.911612</pub-id>
<?supplied-pmid 30117494?><pub-id pub-id-type="pmid">30117494</pub-id></mixed-citation></ref><ref id="pone.0248103.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Jung</surname><given-names>K-K</given-names></name>, <name><surname>Liu</surname><given-names>X-W</given-names></name>, <name><surname>Chirco</surname><given-names>R</given-names></name>, <name><surname>Fridman</surname><given-names>R</given-names></name>, <name><surname>Kim</surname><given-names>H-RC</given-names></name>. <article-title>Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein</article-title>. <source>EMBO J</source>. <year>2006</year>; <volume>25</volume>(<issue>17</issue>): <fpage>3934</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1038/sj.emboj.7601281</pub-id>
<?supplied-pmid 16917503?><pub-id pub-id-type="pmid">16917503</pub-id></mixed-citation></ref><ref id="pone.0248103.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Tugues</surname><given-names>S</given-names></name>, <name><surname>Honjo</surname><given-names>S</given-names></name>, <name><surname>K&#x000f6;nig</surname><given-names>C</given-names></name>, <name><surname>Padhan</surname><given-names>N</given-names></name>, <name><surname>Kroon</surname><given-names>J</given-names></name>, <name><surname>Gualandi</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Tetraspanin CD63 promotes vascular endothelial growth factor receptor 2-&#x003b2;1 integrin complex formation, thereby regulating activation and downstream signaling in endothelial cells in vitro and in vivo</article-title>. <source>J Biol Chem</source>. <year>2013</year>; <volume>288</volume>(<issue>26</issue>): <fpage>19060</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.468199</pub-id>
<?supplied-pmid 23632027?><pub-id pub-id-type="pmid">23632027</pub-id></mixed-citation></ref><ref id="pone.0248103.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Podojil</surname><given-names>JR</given-names></name>, <name><surname>Miller</surname><given-names>SD</given-names></name>. <article-title>Potential targeting of B7-H4 for the treatment of cancer</article-title>. <source>Immunol Rev</source>. <year>2017</year>; <volume>276</volume>(<issue>1</issue>): <fpage>40</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12530</pub-id>
<?supplied-pmid 28258701?><pub-id pub-id-type="pmid">28258701</pub-id></mixed-citation></ref><ref id="pone.0248103.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Ren</surname><given-names>G</given-names></name>. <article-title>Clinical significance of the B7-H4 as a novel prognostic marker in breast cancer</article-title>. <source>Gene</source>. <year>2017</year>; <volume>623</volume>: <fpage>24</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2017.04.003</pub-id>
<?supplied-pmid 28412458?><pub-id pub-id-type="pmid">28412458</pub-id></mixed-citation></ref><ref id="pone.0248103.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Qian</surname><given-names>Y</given-names></name>, <name><surname>Du</surname><given-names>Z</given-names></name>, <name><surname>Xing</surname><given-names>Y</given-names></name>, <name><surname>Zhou</surname><given-names>T</given-names></name>, <name><surname>Chen</surname><given-names>T</given-names></name>, <name><surname>Shi</surname><given-names>M</given-names></name>. <article-title>Interferon regulatory factor 4 (IRF4) is overexpressed in human non&#x02011;small cell lung cancer (NSCLC) and activates the Notch signaling pathway</article-title>. <source>Mol Med Rep</source>. <year>2017</year>; <volume>16</volume>(<issue>5</issue>): <fpage>6034</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2017.7319</pub-id>
<?supplied-pmid 28849037?><pub-id pub-id-type="pmid">28849037</pub-id></mixed-citation></ref><ref id="pone.0248103.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>K</given-names></name>, <name><surname>Kolls</surname><given-names>JK</given-names></name>. <article-title>Interleukin-17A (IL17A)</article-title>. <source>Gene</source>. <year>2017</year>; <volume>614</volume>: <fpage>8</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2017.01.016</pub-id>
<?supplied-pmid 28122268?><pub-id pub-id-type="pmid">28122268</pub-id></mixed-citation></ref><ref id="pone.0248103.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>N</given-names></name>, <name><surname>Shen</surname><given-names>G</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Moustafa</surname><given-names>AA</given-names></name>, <name><surname>Ge</surname><given-names>D</given-names></name>, <name><surname>You</surname><given-names>Z</given-names></name>. <article-title>Interleukin-17 promotes migration and invasion of human cancer cells through upregulation of MTA1 expression</article-title>. <source>Front Oncol.</source>
<year>2019</year>; <volume>9</volume>: <fpage>546</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2019.00546</pub-id>
<?supplied-pmid 31281798?><pub-id pub-id-type="pmid">31281798</pub-id></mixed-citation></ref><ref id="pone.0248103.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Bent</surname><given-names>R</given-names></name>, <name><surname>Moll</surname><given-names>L</given-names></name>, <name><surname>Grabbe</surname><given-names>S</given-names></name>, <name><surname>Bros</surname><given-names>M</given-names></name>. <article-title>Interleukin-1 beta&#x02014;a friend or foe in malignancies?</article-title>
<source>Int J Mol Sci</source>. <year>2018</year>; <volume>19</volume>(<issue>8</issue>): <fpage>2155</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19082155</pub-id>
<?supplied-pmid 30042333?><pub-id pub-id-type="pmid">30042333</pub-id></mixed-citation></ref><ref id="pone.0248103.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Litmanovich</surname><given-names>A</given-names></name>, <name><surname>Khazim</surname><given-names>K</given-names></name>, <name><surname>Cohen</surname><given-names>IR</given-names></name>. <article-title>The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice</article-title>. <source>Oncol Ther</source>. <year>2018</year>; <volume>6</volume>(<issue>2</issue>): <fpage>109</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s40487-018-0089-z</pub-id>
<?supplied-pmid 32700032?><pub-id pub-id-type="pmid">32700032</pub-id></mixed-citation></ref><ref id="pone.0248103.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Kuhn</surname><given-names>DJ</given-names></name>, <name><surname>Smith</surname><given-names>DM</given-names></name>, <name><surname>Pross</surname><given-names>S</given-names></name>, <name><surname>Whiteside</surname><given-names>TL</given-names></name>, <name><surname>Dou</surname><given-names>QP</given-names></name>. <article-title>Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability</article-title>. <source>J Cell Biochem</source>. <year>2003</year>; <volume>89</volume>(<issue>4</issue>): <fpage>824</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.10557</pub-id>
<?supplied-pmid 12858347?><pub-id pub-id-type="pmid">12858347</pub-id></mixed-citation></ref><ref id="pone.0248103.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>T</given-names></name>, <name><surname>Zhou</surname><given-names>C</given-names></name>, <name><surname>Ren</surname><given-names>S</given-names></name>. <article-title>Role of IL-2 in cancer immunotherapy</article-title>. <source>Oncoimmunology</source>. <year>2016</year>; <volume>5</volume>(<issue>6</issue>): <fpage>e1163462</fpage>. <pub-id pub-id-type="doi">10.1080/2162402X.2016.1163462</pub-id>
<?supplied-pmid 27471638?><pub-id pub-id-type="pmid">27471638</pub-id></mixed-citation></ref><ref id="pone.0248103.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Ikutani</surname><given-names>M</given-names></name>, <name><surname>Yanagibashi</surname><given-names>T</given-names></name>, <name><surname>Ogasawara</surname><given-names>M</given-names></name>, <name><surname>Tsuneyama</surname><given-names>K</given-names></name>, <name><surname>Yamamoto</surname><given-names>S</given-names></name>, <name><surname>Hattori</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity</article-title>. <source>J Immunol</source>. <year>2012</year>; <volume>188</volume>(<issue>2</issue>): <fpage>703</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1101270</pub-id>
<?supplied-pmid 22174445?><pub-id pub-id-type="pmid">22174445</pub-id></mixed-citation></ref><ref id="pone.0248103.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Simson</surname><given-names>L</given-names></name>, <name><surname>Ellyard</surname><given-names>JI</given-names></name>, <name><surname>Dent</surname><given-names>LA</given-names></name>, <name><surname>Matthaei</surname><given-names>KI</given-names></name>, <name><surname>Rothenberg</surname><given-names>ME</given-names></name>, <name><surname>Foster</surname><given-names>PS</given-names></name>, <etal>et al</etal>. <article-title>Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance</article-title>. <source>J Immunol</source>. <year>2007</year>; <volume>178</volume>(<issue>7</issue>): <fpage>4222</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.178.7.4222</pub-id>
<?supplied-pmid 17371978?><pub-id pub-id-type="pmid">17371978</pub-id></mixed-citation></ref><ref id="pone.0248103.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Caruso</surname><given-names>JA</given-names></name>, <name><surname>Akli</surname><given-names>S</given-names></name>, <name><surname>Pageon</surname><given-names>L</given-names></name>, <name><surname>Hunt</surname><given-names>KK</given-names></name>, <name><surname>Keyomarsi</surname><given-names>K</given-names></name>. <article-title>The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase</article-title>. <source>Oncogene</source>. <year>2015</year>; <volume>34</volume>(<issue>27</issue>): <fpage>3556</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2014.284</pub-id>
<?supplied-pmid 25195861?><pub-id pub-id-type="pmid">25195861</pub-id></mixed-citation></ref><ref id="pone.0248103.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Caruso</surname><given-names>JA</given-names></name>, <name><surname>Karakas</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Yi</surname><given-names>M</given-names></name>, <name><surname>Albarracin</surname><given-names>C</given-names></name>, <name><surname>Sahin</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence</article-title>. <source>Breast Cancer Res</source>. <year>2014</year>; <volume>16</volume>(<issue>6</issue>): <fpage>3417</fpage>. <pub-id pub-id-type="doi">10.1186/s13058-014-0497-4</pub-id>
<?supplied-pmid 25551582?><pub-id pub-id-type="pmid">25551582</pub-id></mixed-citation></ref><ref id="pone.0248103.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>KS</given-names></name>, <name><surname>Lee</surname><given-names>Y</given-names></name>, <name><surname>Kim</surname><given-names>CM</given-names></name>, <name><surname>Park</surname><given-names>EC</given-names></name>, <name><surname>Choi</surname><given-names>J</given-names></name>, <name><surname>Lim</surname><given-names>DS</given-names></name>, <etal>et al</etal>. <article-title>The protease inhibitor, elafin, induces p53-dependent apoptosis in human melanoma cells</article-title>. <source>Int J Cancer</source>. <year>2010</year>; <volume>127</volume>(<issue>6</issue>): <fpage>1308</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.25125</pub-id>
<?supplied-pmid 20020498?><pub-id pub-id-type="pmid">20020498</pub-id></mixed-citation></ref><ref id="pone.0248103.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>Wilhelmsson</surname><given-names>U</given-names></name>, <name><surname>Eliasson</surname><given-names>C</given-names></name>, <name><surname>Bjerkvig</surname><given-names>R</given-names></name>, <name><surname>Pekny</surname><given-names>M</given-names></name>. <article-title>Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression</article-title>. <source>Oncogene</source>. <year>2003</year>; <volume>22</volume>(<issue>22</issue>): <fpage>3407</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1206372</pub-id>
<?supplied-pmid 12776191?><pub-id pub-id-type="pmid">12776191</pub-id></mixed-citation></ref><ref id="pone.0248103.ref088"><label>88</label><mixed-citation publication-type="journal"><name><surname>Grottke</surname><given-names>A</given-names></name>, <name><surname>Ewald</surname><given-names>F</given-names></name>, <name><surname>Lange</surname><given-names>T</given-names></name>, <name><surname>N&#x000f6;rz</surname><given-names>D</given-names></name>, <name><surname>Herzberger</surname><given-names>C</given-names></name>, <name><surname>Bach</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Downregulation of AKT3 increases migration and metastasis in triple negative breast cancer cells by upregulating S100A4</article-title>. <source>PLoS One</source>. <year>2016</year>; <volume>11</volume>(<issue>1</issue>): <fpage>e0146370</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0146370</pub-id>
<?supplied-pmid 26741489?><pub-id pub-id-type="pmid">26741489</pub-id></mixed-citation></ref><ref id="pone.0248103.ref089"><label>89</label><mixed-citation publication-type="journal"><name><surname>Phung</surname><given-names>TL</given-names></name>, <name><surname>Du</surname><given-names>W</given-names></name>, <name><surname>Xue</surname><given-names>Q</given-names></name>, <name><surname>Ayyaswamy</surname><given-names>S</given-names></name>, <name><surname>Gerald</surname><given-names>D</given-names></name>, <name><surname>Antonello</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>AKT1 and AKT3 exert opposing roles in the regulation of vascular tumor growth</article-title>. <source>Cancer Res</source>. <year>2015</year>; <volume>75</volume>(<issue>1</issue>): <fpage>40</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2961</pub-id>
<?supplied-pmid 25388284?><pub-id pub-id-type="pmid">25388284</pub-id></mixed-citation></ref><ref id="pone.0248103.ref090"><label>90</label><mixed-citation publication-type="journal"><name><surname>Feng</surname><given-names>S</given-names></name>, <name><surname>Song</surname><given-names>J</given-names></name>. <article-title>Relationship of beta-glucuronidase to differentiation and invasion of human colorectal carcinoma</article-title>. <source>Chin Med J</source>. <year>1999</year>; <volume>112</volume>(<issue>9</issue>): <fpage>854</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 11717961?><pub-id pub-id-type="pmid">11717961</pub-id></mixed-citation></ref><ref id="pone.0248103.ref091"><label>91</label><mixed-citation publication-type="journal"><name><surname>Feng</surname><given-names>S</given-names></name>, <name><surname>Song</surname><given-names>JD</given-names></name>. <article-title>Determination of &#x003b2;-glucuronidase in human colorectal carcinoma cell lines</article-title>. <source>World J Gastroenterol</source>. <year>1997</year>; <volume>3</volume>(<issue>4</issue>): <fpage>251</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v3.i4.251</pub-id>
<?supplied-pmid 27053883?><pub-id pub-id-type="pmid">27053883</pub-id></mixed-citation></ref><ref id="pone.0248103.ref092"><label>92</label><mixed-citation publication-type="journal"><name><surname>Sui</surname><given-names>H</given-names></name>, <name><surname>Shi</surname><given-names>C</given-names></name>, <name><surname>Yan</surname><given-names>Z</given-names></name>, <name><surname>Wu</surname><given-names>M</given-names></name>. <article-title>Overexpression of cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer</article-title>. <source>Oncotarget</source>. <year>2016</year>; <volume>7</volume>(<issue>29</issue>): <fpage>45995</fpage>&#x02013;<lpage>6001</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.10276</pub-id>
<?supplied-pmid 27351223?><pub-id pub-id-type="pmid">27351223</pub-id></mixed-citation></ref><ref id="pone.0248103.ref093"><label>93</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Yang</surname><given-names>Z</given-names></name>, <name><surname>Pan</surname><given-names>Z</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>. <article-title>Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer</article-title>. <source>Oncol Rep</source>. <year>2014</year>; <volume>31</volume>(<issue>3</issue>): <fpage>1334</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.3892/or.2014.2967</pub-id>
<?supplied-pmid 24402045?><pub-id pub-id-type="pmid">24402045</pub-id></mixed-citation></ref><ref id="pone.0248103.ref094"><label>94</label><mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Dong</surname><given-names>D</given-names></name>, <name><surname>Zhang</surname><given-names>B</given-names></name>, <name><surname>Xue</surname><given-names>Y</given-names></name>, <name><surname>Shang</surname><given-names>P</given-names></name>. <article-title>Transferrin receptor 1 in cancer: a new sight for cancer therapy</article-title>. <source>Am J Cancer Res</source>. <year>2018</year>; <volume>8</volume>(<issue>6</issue>): <fpage>916</fpage>&#x02013;<lpage>31</lpage>. <?supplied-pmid 30034931?><pub-id pub-id-type="pmid">30034931</pub-id></mixed-citation></ref><ref id="pone.0248103.ref095"><label>95</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Zhong</surname><given-names>J</given-names></name>, <name><surname>Yang</surname><given-names>R</given-names></name>. <article-title>COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway</article-title>. <source>Mol Med Rep</source>. <year>2018</year>; <volume>17</volume>(<issue>4</issue>): <fpage>5037</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2018.8533</pub-id>
<?supplied-pmid 29393423?><pub-id pub-id-type="pmid">29393423</pub-id></mixed-citation></ref><ref id="pone.0248103.ref096"><label>96</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Shen</surname><given-names>JX</given-names></name>, <name><surname>Wu</surname><given-names>HT</given-names></name>, <name><surname>Li</surname><given-names>XL</given-names></name>, <name><surname>Wen</surname><given-names>XF</given-names></name>, <name><surname>Du</surname><given-names>CW</given-names></name>, <etal>et al</etal>. <article-title>Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target</article-title>. <source>Discov Med</source>. <year>2018</year>; <volume>25</volume>(<issue>139</issue>): <fpage>211</fpage>&#x02013;<lpage>23</lpage>. <?supplied-pmid 29906404?><pub-id pub-id-type="pmid">29906404</pub-id></mixed-citation></ref><ref id="pone.0248103.ref097"><label>97</label><mixed-citation publication-type="journal"><name><surname>Piper</surname><given-names>AJ</given-names></name>, <name><surname>Clark</surname><given-names>JL</given-names></name>, <name><surname>Mercado-Matos</surname><given-names>J</given-names></name>, <name><surname>Matthew-Onabanjo</surname><given-names>AN</given-names></name>, <name><surname>Hsieh</surname><given-names>C-C</given-names></name>, <name><surname>Akalin</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Insulin receptor substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC)</article-title>. <source>PLoS One</source>. <year>2019</year>; <volume>14</volume>(<issue>8</issue>): <fpage>e0220567</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0220567</pub-id>
<?supplied-pmid 31393907?><pub-id pub-id-type="pmid">31393907</pub-id></mixed-citation></ref><ref id="pone.0248103.ref098"><label>98</label><mixed-citation publication-type="journal"><name><surname>You</surname><given-names>HL</given-names></name>, <name><surname>Liu</surname><given-names>TT</given-names></name>, <name><surname>Weng</surname><given-names>SW</given-names></name>, <name><surname>Chen</surname><given-names>CH</given-names></name>, <name><surname>Wei</surname><given-names>YC</given-names></name>, <name><surname>Eng</surname><given-names>HL</given-names></name>, <etal>et al</etal>. <article-title>Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma</article-title>. <source>Oncol Lett</source>. <year>2018</year>; <volume>16</volume>(<issue>4</issue>): <fpage>5505</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2018.9284</pub-id>
<?supplied-pmid 30250623?><pub-id pub-id-type="pmid">30250623</pub-id></mixed-citation></ref><ref id="pone.0248103.ref099"><label>99</label><mixed-citation publication-type="journal"><name><surname>Kubota</surname><given-names>T</given-names></name>, <name><surname>Inoue</surname><given-names>M</given-names></name>, <name><surname>Kubota</surname><given-names>N</given-names></name>, <name><surname>Takamoto</surname><given-names>I</given-names></name>, <name><surname>Mineyama</surname><given-names>T</given-names></name>, <name><surname>Iwayama</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Downregulation of macrophage Irs2 by hyperinsulinemia impairs IL-4-indeuced M2a-subtype macrophage activation in obesity</article-title>. <source>Nat Commun</source>. <year>2018</year>; <volume>9</volume>(<issue>1</issue>): <fpage>4863</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-07358-9</pub-id>
<?supplied-pmid 30451856?><pub-id pub-id-type="pmid">30451856</pub-id></mixed-citation></ref><ref id="pone.0248103.ref100"><label>100</label><mixed-citation publication-type="journal"><name><surname>Kubota</surname><given-names>T</given-names></name>, <name><surname>Kubota</surname><given-names>N</given-names></name>, <name><surname>Kadowaki</surname><given-names>T</given-names></name>. <article-title>Imbalanced insulin actions in obesity and type 2 diabetes: key mouse models of insulin signaling pathway</article-title>. <source>Cell Metab</source>. <year>2017</year>; <volume>25</volume>(<issue>4</issue>): <fpage>797</fpage>&#x02013;<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2017.03.004</pub-id>
<?supplied-pmid 28380373?><pub-id pub-id-type="pmid">28380373</pub-id></mixed-citation></ref><ref id="pone.0248103.ref101"><label>101</label><mixed-citation publication-type="journal"><name><surname>Kuroki</surname><given-names>M</given-names></name>, <name><surname>Abe</surname><given-names>H</given-names></name>, <name><surname>Imakiirei</surname><given-names>T</given-names></name>, <name><surname>Liao</surname><given-names>S</given-names></name>, <name><surname>Uchida</surname><given-names>H</given-names></name>, <name><surname>Yamauchi</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Identification and comparison of residues critical for cell-adhesion activities of two neutrophil CD66 antigens, CEACAM6 and CEACAM8</article-title>. <source>J Leukoc Biol</source>. <year>2001</year>; <volume>70</volume>(<issue>4</issue>): <fpage>543</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.70.4.543</pub-id>
<?supplied-pmid 11590190?><pub-id pub-id-type="pmid">11590190</pub-id></mixed-citation></ref><ref id="pone.0248103.ref102"><label>102</label><mixed-citation publication-type="book"><name><surname>Horst</surname><given-names>AK</given-names></name>, <name><surname>Wagener</surname><given-names>C</given-names></name>. <chapter-title>CEA-related CAMs</chapter-title>. In: <name><surname>Behrens</surname><given-names>J</given-names></name>, <name><surname>Nelson</surname><given-names>WJ</given-names></name>, editors. <source>Cell Adhesion. Handbook of Experimental Pharmacology.</source> Vol. <volume>165</volume>, <edition designator="1">1st ed</edition>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2004</year>. p. <fpage>283</fpage>&#x02013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-540-68170-0_10</pub-id>
<?supplied-pmid 20455097?><pub-id pub-id-type="pmid">20455097</pub-id></mixed-citation></ref><ref id="pone.0248103.ref103"><label>103</label><mixed-citation publication-type="journal"><name><surname>Iwabuchi</surname><given-names>E</given-names></name>, <name><surname>Miki</surname><given-names>Y</given-names></name>, <name><surname>Onodera</surname><given-names>Y</given-names></name>, <name><surname>Shibahara</surname><given-names>Y</given-names></name>, <name><surname>Takagi</surname><given-names>K</given-names></name>, <name><surname>Suzuki</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells</article-title>. <source>Clin Exp Metastasis</source>. <year>2019</year>; <volume>36</volume>(<issue>5</issue>): <fpage>423</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1007/s10585-019-09981-2</pub-id>
<?supplied-pmid 31222613?><pub-id pub-id-type="pmid">31222613</pub-id></mixed-citation></ref><ref id="pone.0248103.ref104"><label>104</label><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>M</given-names></name>, <name><surname>Yin</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>B</given-names></name>, <name><surname>Bian</surname><given-names>Z</given-names></name>, <name><surname>Quan</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1</article-title>. <source>Protein Cell</source>. <year>2014</year>; <volume>5</volume>(<issue>11</issue>): <fpage>851</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1007/s13238-014-0093-5</pub-id>
<?supplied-pmid 25149074?><pub-id pub-id-type="pmid">25149074</pub-id></mixed-citation></ref><ref id="pone.0248103.ref105"><label>105</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>Z</given-names></name>, <name><surname>Zhang</surname><given-names>N</given-names></name>, <name><surname>Zha</surname><given-names>L</given-names></name>, <name><surname>Mao</surname><given-names>HC</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Xiang</surname><given-names>JF</given-names></name>, <etal>et al</etal>. <article-title>Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma</article-title>. <source>Asian Pac J Cancer Prev</source>. <year>2014</year>; <volume>15</volume>(<issue>2</issue>): <fpage>989</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.7314/apjcp.2014.15.2.989</pub-id>
<?supplied-pmid 24568530?><pub-id pub-id-type="pmid">24568530</pub-id></mixed-citation></ref><ref id="pone.0248103.ref106"><label>106</label><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>He</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Gao</surname><given-names>H</given-names></name>. <article-title>Expression of Gli1 and Wnt2B correlates with progression and clinical outcome of pancreatic cancer</article-title>. <source>Int J Clin Exp Pathol</source>. <year>2014</year>; <volume>7</volume>(<issue>7</issue>): <fpage>4531</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 25120849?><pub-id pub-id-type="pmid">25120849</pub-id></mixed-citation></ref><ref id="pone.0248103.ref107"><label>107</label><mixed-citation publication-type="journal"><name><surname>Katoh</surname><given-names>M.</given-names></name>
<article-title>WNT2B: comparative integromics and clinical applications</article-title>. <source>Int J Mol Med</source>. <year>2005</year>; <volume>16</volume>(<issue>6</issue>): <fpage>1103</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.16.6.1103</pub-id>
<?supplied-pmid 16273293?><pub-id pub-id-type="pmid">16273293</pub-id></mixed-citation></ref><ref id="pone.0248103.ref108"><label>108</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Yu</surname><given-names>X</given-names></name>, <name><surname>Yang</surname><given-names>L</given-names></name>. <article-title>MiR-145 inhibits cervical cancer progression and metastasis by targeting WNT2B by Wnt/&#x003b2;-catenin pathway</article-title>. <source>Int J Clin Exp Pathol</source>. <year>2019</year>; <volume>12</volume>(<issue>10</issue>): <fpage>3740</fpage>&#x02013;<lpage>51</lpage>. <?supplied-pmid 31933762?><pub-id pub-id-type="pmid">31933762</pub-id></mixed-citation></ref><ref id="pone.0248103.ref109"><label>109</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>H</given-names></name>, <name><surname>Cai</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Wu</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Zuo</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Membrane palmitoylated protein 3 promotes hepatocellular carcinoma cell migration and invasion via up-regulating matrix metalloproteinase 1</article-title>. <source>Cancer Lett</source>. <year>2014</year>; <volume>344</volume>(<issue>1</issue>): <fpage>74</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2013.10.017</pub-id>
<?supplied-pmid 24513266?><pub-id pub-id-type="pmid">24513266</pub-id></mixed-citation></ref><ref id="pone.0248103.ref110"><label>110</label><mixed-citation publication-type="book"><name><surname>Bill</surname><given-names>CA</given-names></name>, <name><surname>Vines</surname><given-names>CM</given-names></name>. <chapter-title>Phospholipase C</chapter-title>. In: <name><surname>Islam</surname><given-names>S</given-names></name>, editor. <source>Calcium Signaling. Advances in Experimental Medicine and Biology</source>. Vol. <volume>1131</volume>, <edition designator="2">2nd ed</edition>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer Nature Switzerland</publisher-name>; <year>2019</year>. p. <fpage>215</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-030-12457-1_9</pub-id>
<?supplied-pmid 31646512?><pub-id pub-id-type="pmid">31646512</pub-id></mixed-citation></ref><ref id="pone.0248103.ref111"><label>111</label><mixed-citation publication-type="journal"><name><surname>Stanislaus</surname><given-names>A</given-names></name>, <name><surname>Bakhtiar</surname><given-names>A</given-names></name>, <name><surname>Salleh</surname><given-names>D</given-names></name>, <name><surname>Tiash</surname><given-names>S</given-names></name>, <name><surname>Fatemian</surname><given-names>T</given-names></name>, <name><surname>Hossain</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel</article-title>. <source>Cancer Cell Int</source>. <year>2012</year>; <volume>12</volume>(<issue>1</issue>): <fpage>30</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2867-12-30</pub-id>
<?supplied-pmid 22709569?><pub-id pub-id-type="pmid">22709569</pub-id></mixed-citation></ref><ref id="pone.0248103.ref112"><label>112</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>D</given-names></name>, <name><surname>Lian</surname><given-names>F</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>. <article-title>PLCG2 promotes hepatocyte proliferation in vitro via NF-&#x003ba;B and ERK pathway by targeting bcl2, myc and ccnd1</article-title>. <source>Artif Cells Nanomed Biotechnol</source>. <year>2019</year>; <volume>47</volume>(<issue>1</issue>): <fpage>3786</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1080/21691401.2019.1669616</pub-id>
<?supplied-pmid 31549850?><pub-id pub-id-type="pmid">31549850</pub-id></mixed-citation></ref><ref id="pone.0248103.ref113"><label>113</label><mixed-citation publication-type="journal"><name><surname>Zeng</surname><given-names>B</given-names></name>, <name><surname>Zhou</surname><given-names>M</given-names></name>, <name><surname>Wu</surname><given-names>HT</given-names></name>, <name><surname>Xiong</surname><given-names>Z</given-names></name>. <article-title>SPP1 promotes ovarian cancer progression via integrin &#x003b2;1/FAK/AKT signaling pathway</article-title>. <source>OncoTargets and Therapy</source>. <year>2018</year>; <volume>11</volume>: <fpage>1333</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.2147/OTT.S154215</pub-id>
<?supplied-pmid 29559792?><pub-id pub-id-type="pmid">29559792</pub-id></mixed-citation></ref><ref id="pone.0248103.ref114"><label>114</label><mixed-citation publication-type="journal"><name><surname>Lamort</surname><given-names>A-S</given-names></name>, <name><surname>Giopanou</surname><given-names>I</given-names></name>, <name><surname>Psallidas</surname><given-names>I</given-names></name>, <name><surname>Stathopoulos</surname><given-names>GT</given-names></name>. <article-title>Osteopontin as a link between inflammation and cancer: the thorax in the spotlight</article-title>. <source>Cells</source>. <year>2019</year>; <volume>8</volume>(<issue>8</issue>): <fpage>815</fpage>. <pub-id pub-id-type="doi">10.3390/cells8080815</pub-id>
<?supplied-pmid 31382483?><pub-id pub-id-type="pmid">31382483</pub-id></mixed-citation></ref><ref id="pone.0248103.ref115"><label>115</label><mixed-citation publication-type="journal"><name><surname>Pietil&#x000e4;</surname><given-names>M</given-names></name>, <name><surname>Sahgal</surname><given-names>P</given-names></name>, <name><surname>Peuhu</surname><given-names>E</given-names></name>, <name><surname>J&#x000e4;ntti</surname><given-names>NZ</given-names></name>, <name><surname>Paatero</surname><given-names>I</given-names></name>, <name><surname>N&#x000e4;rv&#x000e4;</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>SORLA regulates endosomal trafficking and oncogenic fitness of HER2</article-title>. <source>Nat Commun</source>. <year>2019</year>; <volume>10</volume>(<issue>1</issue>): <fpage>2340</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-10275-0</pub-id>
<?supplied-pmid 31138794?><pub-id pub-id-type="pmid">31138794</pub-id></mixed-citation></ref><ref id="pone.0248103.ref116"><label>116</label><mixed-citation publication-type="journal"><name><surname>Claesson-Welsh</surname><given-names>L</given-names></name>, <name><surname>Welsh</surname><given-names>M</given-names></name>. <article-title>VEGFA and tumour angiogenesis</article-title>. <source>J Intern Med</source>. <year>2013</year>; <volume>273</volume>(<issue>2</issue>): <fpage>114</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1111/joim.12019</pub-id>
<?supplied-pmid 23216836?><pub-id pub-id-type="pmid">23216836</pub-id></mixed-citation></ref><ref id="pone.0248103.ref117"><label>117</label><mixed-citation publication-type="journal"><name><surname>Zeng</surname><given-names>F-C</given-names></name>, <name><surname>Zeng</surname><given-names>M-Q</given-names></name>, <name><surname>Huang</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>Y-L</given-names></name>, <name><surname>Gao</surname><given-names>B-M</given-names></name>, <name><surname>Chen</surname><given-names>J-J</given-names></name>, <etal>et al</etal>. <article-title>Downregulation of VEGFA inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of renal clear cell carcinoma</article-title>. <source>OncoTargets and Therapy</source>. <year>2016</year>; <volume>9</volume>: <fpage>2131</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.2147/OTT.S98002</pub-id>
<?supplied-pmid 27110129?><pub-id pub-id-type="pmid">27110129</pub-id></mixed-citation></ref><ref id="pone.0248103.ref118"><label>118</label><mixed-citation publication-type="journal"><name><surname>Menges</surname><given-names>CW</given-names></name>, <name><surname>Altomare</surname><given-names>DA</given-names></name>, <name><surname>Testa</surname><given-names>JR</given-names></name>. <article-title>FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis</article-title>. <source>Cell Cycle</source>. <year>2009</year>; <volume>8</volume>(<issue>16</issue>): <fpage>2528</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.4161/cc.8.16.9280</pub-id>
<?supplied-pmid 19597341?><pub-id pub-id-type="pmid">19597341</pub-id></mixed-citation></ref><ref id="pone.0248103.ref119"><label>119</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>AQ</given-names></name>, <name><surname>Xie</surname><given-names>Z</given-names></name>, <name><surname>Chen</surname><given-names>XN</given-names></name>, <name><surname>Feng</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>JW</given-names></name>, <name><surname>Qin</surname><given-names>FJ</given-names></name>, <etal>et al</etal>. <article-title>Fas-associated factor 1 inhibits tumor growth by suppressing Helicobacter pylori-induced activation of NF-&#x003ba;B signaling in human gastric carcinoma</article-title>. <source>Oncotarget</source>. <year>2017</year>; <volume>8</volume>(<issue>5</issue>): <fpage>7999</fpage>&#x02013;<lpage>8009</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.14033</pub-id>
<?supplied-pmid 28030825?><pub-id pub-id-type="pmid">28030825</pub-id></mixed-citation></ref><ref id="pone.0248103.ref120"><label>120</label><mixed-citation publication-type="journal"><name><surname>Holbro</surname><given-names>T</given-names></name>, <name><surname>Beerli</surname><given-names>RR</given-names></name>, <name><surname>Maurer</surname><given-names>F</given-names></name>, <name><surname>Koziczak</surname><given-names>M</given-names></name>, <name><surname>Barbas</surname><given-names>CF, 3rd</given-names></name>, <name><surname>Hynes</surname><given-names>NE</given-names></name>. <article-title>The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2003</year>; <volume>100</volume>(<issue>15</issue>): <fpage>8933</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1537685100</pub-id>
<?supplied-pmid 12853564?><pub-id pub-id-type="pmid">12853564</pub-id></mixed-citation></ref><ref id="pone.0248103.ref121"><label>121</label><mixed-citation publication-type="journal"><name><surname>Saito</surname><given-names>S</given-names></name>, <name><surname>Yamamoto</surname><given-names>H</given-names></name>, <name><surname>Mukaisho</surname><given-names>K-I</given-names></name>, <name><surname>Sato</surname><given-names>S</given-names></name>, <name><surname>Higo</surname><given-names>T</given-names></name>, <name><surname>Hattori</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Mechanisms underlying cancer progression caused by ezrin overexpression in tongue squamous cell carcinoma</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>(<issue>1</issue>): <fpage>e54881</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0054881</pub-id>
<?supplied-pmid 23357878?><pub-id pub-id-type="pmid">23357878</pub-id></mixed-citation></ref><ref id="pone.0248103.ref122"><label>122</label><mixed-citation publication-type="journal"><name><surname>Hunter</surname><given-names>KW</given-names></name>. <article-title>Ezrin, a key component in tumor metastasis</article-title>. <source>Trends Mol Med</source>. <year>2004</year>; <volume>10</volume>(<issue>5</issue>): <fpage>201</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2004.03.001</pub-id>
<?supplied-pmid 15121044?><pub-id pub-id-type="pmid">15121044</pub-id></mixed-citation></ref><ref id="pone.0248103.ref123"><label>123</label><mixed-citation publication-type="journal"><name><surname>Schimm&#x000f6;ller</surname><given-names>F</given-names></name>, <name><surname>D&#x000ed;az</surname><given-names>E</given-names></name>, <name><surname>M&#x000fc;hlbauer</surname><given-names>B</given-names></name>, <name><surname>Pfeffer</surname><given-names>SR</given-names></name>. <article-title>Characterization of a 76 kDa endosomal, multispanning membrane protein that is highly conserved throughout evolution</article-title>. <source>Gene</source>. <year>1998</year>; <volume>216</volume>(<issue>2</issue>): <fpage>311</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/s0378-1119(98)00349-7</pub-id>
<?supplied-pmid 9729438?><pub-id pub-id-type="pmid">9729438</pub-id></mixed-citation></ref><ref id="pone.0248103.ref124"><label>124</label><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>CR</given-names></name>, <name><surname>Maile</surname><given-names>M</given-names></name>, <name><surname>Blaney</surname><given-names>P</given-names></name>, <name><surname>Hellweg</surname><given-names>SR</given-names></name>, <name><surname>Strauss</surname><given-names>A</given-names></name>, <name><surname>Durose</surname><given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Transposon mutagenesis screen in mice identifies TM9SF2 as a novel colorectal cancer oncogene</article-title>. <source>Sci Rep</source>. <year>2018</year>; <volume>8</volume>(<issue>1</issue>): <fpage>15327</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-33527-3</pub-id>
<?supplied-pmid 30333512?><pub-id pub-id-type="pmid">30333512</pub-id></mixed-citation></ref><ref id="pone.0248103.ref125"><label>125</label><mixed-citation publication-type="journal"><name><surname>Abou-Sharieha</surname><given-names>S</given-names></name>, <name><surname>Sugii</surname><given-names>Y</given-names></name>, <name><surname>Tuoya</surname></name>, <name><surname>Yu</surname><given-names>D</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Tokutaka</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Identification of TM9SF2 as a candidate of the cell surface marker common to breast carcinoma cells</article-title>. <source>Chin J Clin Oncol</source>. <year>2009</year>; <volume>6</volume>: <fpage>1</fpage>. <pub-id pub-id-type="doi">10.1007/s11805-009-0001-6</pub-id></mixed-citation></ref><ref id="pone.0248103.ref126"><label>126</label><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>X</given-names></name>, <name><surname>Guo</surname><given-names>B</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Zhu</surname><given-names>B</given-names></name>. <article-title>Tissue factor in tumor microenvironment: a systematic review</article-title>. <source>J Hematol Oncol</source>. <year>2014</year>; <volume>7</volume>: <fpage>54</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-014-0054-8</pub-id>
<?supplied-pmid 25084809?><pub-id pub-id-type="pmid">25084809</pub-id></mixed-citation></ref><ref id="pone.0248103.ref127"><label>127</label><mixed-citation publication-type="journal"><name><surname>White</surname><given-names>NMA</given-names></name>, <name><surname>Masui</surname><given-names>O</given-names></name>, <name><surname>Newsted</surname><given-names>D</given-names></name>, <name><surname>Scorilas</surname><given-names>A</given-names></name>, <name><surname>Romaschin</surname><given-names>AD</given-names></name>, <name><surname>Bjarnason</surname><given-names>GA</given-names></name>, <etal>et al</etal>. <article-title>Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis</article-title>. <source>Br J Cancer</source>. <year>2014</year>; <volume>110</volume>(<issue>5</issue>): <fpage>1250</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2013.828</pub-id>
<?supplied-pmid 24496460?><pub-id pub-id-type="pmid">24496460</pub-id></mixed-citation></ref><ref id="pone.0248103.ref128"><label>128</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>J-M</given-names></name>, <name><surname>Tseng</surname><given-names>C-W</given-names></name>, <name><surname>Lin</surname><given-names>C-C</given-names></name>, <name><surname>Law</surname><given-names>C-H</given-names></name>, <name><surname>Chien</surname><given-names>Y-A</given-names></name>, <name><surname>Kuo</surname><given-names>W-H</given-names></name>, <etal>et al</etal>. <article-title>Upregulation of LGALS1 is associated with oral cancer metastasis</article-title>. <source>Ther Adv Med Oncol</source>. <year>2018</year>; <volume>10</volume>: <fpage>1</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1177/1758835918794622</pub-id>
<?supplied-pmid 30159048?><pub-id pub-id-type="pmid">30159048</pub-id></mixed-citation></ref><ref id="pone.0248103.ref129"><label>129</label><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>Z-W</given-names></name>, <name><surname>Dong</surname><given-names>K</given-names></name>, <name><surname>Zhang</surname><given-names>H-Z</given-names></name>. <article-title>The roles of CD73 in cancer</article-title>. <source>Biomed Res Int</source>. <year>2014</year>; <volume>2014</volume>: <fpage>460654</fpage>. <pub-id pub-id-type="doi">10.1155/2014/460654</pub-id>
<?supplied-pmid 25126561?><pub-id pub-id-type="pmid">25126561</pub-id></mixed-citation></ref><ref id="pone.0248103.ref130"><label>130</label><mixed-citation publication-type="journal"><name><surname>Gilder</surname><given-names>AS</given-names></name>, <name><surname>Natali</surname><given-names>L</given-names></name>, <name><surname>Van Dyk</surname><given-names>DM</given-names></name>, <name><surname>Zalfa</surname><given-names>C</given-names></name>, <name><surname>Banki</surname><given-names>MA</given-names></name>, <name><surname>Pizzo</surname><given-names>DP</given-names></name>, <etal>et al</etal>. <article-title>The urokinase receptor induces a mesenchymal gene expression signature in glioblastoma cells and promotes tumor cell survival in neurospheres</article-title>. <source>Sci Rep</source>. <year>2018</year>; <volume>8</volume>(<issue>1</issue>): <fpage>2982</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-21358-1</pub-id>
<?supplied-pmid 29445239?><pub-id pub-id-type="pmid">29445239</pub-id></mixed-citation></ref></ref-list></back></article>